

















  





















































<!DOCTYPE html>
<html xmlns="https://www.w3.org/1999/xhtml" lang='en'>
<head>  
  <meta http-equiv="X-UA-Compatible" content="IE=edge" />
  <meta name="viewport" content="width=device-width, initial-scale=1">
  <meta http-equiv="content-type" content="text/html; charset=UTF-8" />
    <meta name="referrer" content="origin-when-cross-origin"/>
  <title>A Study of Emicizumab Administered Subcutaneously (SC) in Pediatric Participants With Hemophilia A and Factor VIII (FVIII) Inhibitors - Full Text View - ClinicalTrials.gov</title>
    <link href="/ct2/show/NCT02795767" rel="canonical"/>
    
  <!-- Twitter Card data -->
  <meta name="twitter:card" content="summary">
  <meta name="twitter:image" content="https://clinicaltrials.gov/ct2/html/images/ct.gov-nlm-nih-square-logo.png?v1">

  <!-- Open Graph data -->
  <meta property="og:type" content="article" />
  <meta property="og:title" content="A Study of Emicizumab Administered Subcutaneously (SC) in Pediatric Participants With Hemophilia A and Factor VIII (FVIII) Inhibitors - Full Text View - ClinicalTrials.gov">
  <meta property="og:image" content="https://clinicaltrials.gov/ct2/html/images/ct.gov-nlm-nih-square-logo.png?v1">
    <meta property="og:description" content="A Study of Emicizumab Administered Subcutaneously (SC) in Pediatric Participants With Hemophilia A and Factor VIII (FVIII) Inhibitors - Full Text View.">
  <meta property="og:url" content="https://clinicaltrials.gov/ct2/show/NCT02795767">
    
  <link rel="shortcut icon" href="/ct2/html/images/favicon.ico" />
  <link rel='apple-touch-icon-precomposed' href='/ct2/html/images/apple-touch-icon-144x144.png' sizes='144x144'>
  <link rel='apple-touch-icon-precomposed' href='/ct2/html/images/apple-touch-icon-114x114.png' sizes='114x114'>
  <link rel='apple-touch-icon-precomposed' href='/ct2/html/images/apple-touch-icon-72x72.png'   sizes='72x72'>
  <link rel='apple-touch-icon-precomposed' href='/ct2/html/images/apple-touch-icon-precomposed.png' >
  <link rel='apple-touch-icon-precomposed' href='/ct2/html/images/apple-touch-icon.png' >

  <link rel="stylesheet" type="text/css" href="/ct2/html/jquery/css/superfish.css?v=44" media="screen" />
  <link rel="stylesheet" type="text/css" href="/ct2/html/jquery/css/superfish-vertical.css?v=44" media="screen" />
  <link rel="stylesheet" type="text/css" href="/ct2/html/css/glossary.css?v=44" />
  <link rel="stylesheet" type="text/css" href="/ct2/html/css/base.css?v=44" />
  <link rel="stylesheet" type="text/css" href="/ct2/html/css/print.css?v=44" media="print" />
  <link rel="stylesheet" href="/ct2/html/css/w3-ct.css?v=44" type="text/css" />
  <!--[if lt IE 9]>
	<link rel="stylesheet" href="/ct2/html/css/w3-ct-oldIE.css?v=44" type="text/css" />
  <![endif]-->
   	
  <link rel="preconnect" href="https://use.fontawesome.com">
  <link rel="preconnect" href="https://www.ncbi.nlm.nih.gov">
  
  <script src="https://use.fontawesome.com/20a31629ec.js"></script>
<!--[if lte IE 7]>
       <link href="/ct2/html/css/target-IE7-and-below.css" rel="stylesheet" type="text/css">
<![endif]-->

<style type="text/css">
  h2 
  {
      background-color: #EAEAEA;
  }
</style>
<link href="/ct2/html/css/trial-record.css?v=44" rel="stylesheet" type="text/css" />

	<script type="text/javascript" src="/ct2/html/jquery/js/jquery.min.js?v=44"></script><noscript></noscript>
<script type="text/javascript" async src="/ct2/html/jquery/js/superclick.min.js?v=44"></script><noscript></noscript>
<script type="text/javascript" async src="/ct2/html/js/ct.js?v=44"></script><noscript></noscript>
<script type="text/javascript" async src="/ct2/html/js/ctmenu.js?v=44"></script><noscript></noscript>
<script>
var theURL = "/ct2/show/NCT02795767"+window.location.hash;
history.replaceState(null,null,theURL);
</script>

  <meta name="ncbi_sid" content="4ec8b7bc0e309146_36c1a9SID"/>
  <meta name="ncbi_app" content="ctgov"/>
  <meta name="ncbi_db" content="ctgov"/>
  <meta name="ncbi_pdid" content="show_study"/>
  <meta name="ncbi_pcid" content="NCT02795767"/>
  <meta name="ncbi_ctreqid" content="R990F26m"/>
  <meta name="ncbi_ctsessid" content="S990Dl4A"/>
  <meta name="ncbi_ctipid" content="IZ45kPwP"/>
  <meta name="ncbi_cthost" content="w12"/>
</head>


<body> 
<script type="text/javascript">
    jQuery.getScript("https://www.ncbi.nlm.nih.gov/core/alerts/alerts.js", function () {
      galert(['#alert_banner', 'body &gt; *:nth-child(1)'])});
</script>

<div id="alert_banner"></div>

<!--BEGIN QUALTRICS WEBSITE FEEDBACK SNIPPET-->
<script type='text/javascript'>
(function(){var g=function(e,h,f,g){
this.get=function(a){for(var a=a+"=",c=document.cookie.split(";"),b=0,e=c.length;b<e;b++){for(var d=c[b];" "==d.charAt(0);)d=d.substring(1,d.length);if(0==d.indexOf(a))return d.substring(a.length,d.length)}return null};
this.set=function(a,c){var b="",b=new Date;b.setTime(b.getTime()+6048E5);b="; expires="+b.toGMTString();document.cookie=a+"="+c+b+"; path=/; "};
this.check=function(){var a=this.get(f);if(a)a=a.split(":");else if(100!=e)"v"==h&&(e=Math.random()>=e/100?0:100),a=[h,e,0],this.set(f,a.join(":"));else return!0;var c=a[1];if(100==c)return!0;switch(a[0]){case "v":return!1;case "r":return c=a[2]%Math.floor(100/c),a[2]++,this.set(f,a.join(":")),!c}return!0};
this.go=function(){if(this.check()){var a=document.createElement("script");a.type="text/javascript";a.src=g+ "&t=" + (new Date()).getTime();document.body&&document.body.appendChild(a)}};
this.start=function(){var a=this;window.addEventListener?window.addEventListener("load",function(){a.go()},!1):window.attachEvent&&window.attachEvent("onload",function(){a.go()})}};
try{(new g(100,"r","QSI_S_ZN_7WHWRcRMBs9xWYd","https://zn7whwrcrmbs9xwyd-nlmenterprise.siteintercept.qualtrics.com/WRSiteInterceptEngine/?Q_ZID=ZN_7WHWRcRMBs9xWYd")).start()}catch(i){}})();
</script><div id='ZN_7WHWRcRMBs9xWYd'><!--DO NOT REMOVE-CONTENTS PLACED HERE--></div>
<!--END WEBSITE FEEDBACK SNIPPET-->
<div id="glossary" class="glossary"
    aria-describedby="glossary-result" aria-hidden="true">
  <button
      title="Close glossary"
      class="js-glossary-close button button--close js-glossary-toggle usa-button-unstyled"
    ><span class="usa-sr-only">Hide glossary</span>
    <i class="fa fa-times" aria-hidden="true"></i>
  </button>
  <h4 class="glossary-heading">Glossary</h4>
  <p>
  Study record managers: refer to the <a href="https://clinicaltrials.gov/ct2/manage-recs/resources#DataElement"><span style="text-decoration:underline">Data Element Definitions</span></a> if submitting registration or results information.
  </p>
  <p>
  <label for="glossary-search" class="label">Search for terms</label>
  </p>
  <span class="clearable-input">
  <input id="glossary-search" class="js-glossary-search">
   <span data-clear-input="" class="js-glossary-clear button js-glossary-toggle usa-button-unstyled">x</span>
  </span>
  <div class="glossary__content" id="glossary-result">
    <ul class="js-glossary-list"></ul>
  </div>
</div>

<div id="skip"> <a href="#main-content">Skip to Main Content</a> </div>


<script type="text/javascript" src="/ct2/html/js/working.js"></script><noscript></noscript>
<div id="workingDim" class="ct-dim">
  <div id="workingIndicator" class="ct-workingBox" style="text-align:center;vertical-align:middle;">
    <img alt="Working&#8230;" src="/ct2/html/images/working.gif" height="50" >
  </div>
</div>

<div id="wrapper"> 
<div class="ct-inner_wrapper">   			<a href="/ct2/home" style='float:left;border-bottom-width:0;min-width:200px;width:29%;'><img src='/ct2/html/images/ct.gov-nlm-nih-logo.png' alt='ClinicalTrials.gov'/></a>

				<div id="hamburger" class="w3-hide-medium w3-hide-large" style="float:right;border-width:0;display:block;margin-left:1em;padding:4px;"
			title="Show menus">
			<img src="/ct2/html/images/hamburgerMenuIcon.png" alt="ClinicalTrials.gov Menu" style="max-width:30px;cursor:pointer;" 
			 onclick="$('#global-nav-popupMenu').toggle();"/>
		</div>
		<div id="global-nav-popupMenu" class="w3-hide-medium w3-hide-large w3-modal w3-center" 
			 style="display:none;" onclick="$('#global-nav-popupMenu').hide();"> 			<div id="global-nav-popupMenu-content" class="w3-modal-content">
				<div class="w3-container">
				    <span onclick="$('#global-nav-popupMenu').hide();"
				      class="w3-closebtn">&times;</span>
					<ul class="sf-menu sf-vertical">
									<li class="first"><a href="/ct2/search/index">Find Studies<img src="/ct2/html/images/pulldown.png" alt="Find Studies Menu"></a>
			<ul>
                      <li                  ><a                  href="/ct2/home">New Search</a></li>
                      <li                  ><a         href="/ct2/search/advanced">Advanced Search</a></li>
                      <li                  ><a     href="/ct2/search/browse?brwse=cond_cat">See Studies by Topic</a></li>
                      <li                  ><a             href="/ct2/search/map">See Studies on Map</a></li>
                      <li class="new-group"><a           href="/ct2/help/how-find/index">How to Search</a></li>
                      <li                  ><a href="/ct2/help/how-use-search-results">How to Use Search Results</a></li>
                      <li                  ><a        href="/ct2/help/how-find/find-study-results">How to Find Results of Studies</a></li>
                      <li                  ><a          href="/ct2/help/how-read-study">How to Read a Study Record</a></li>
			</ul>
			</li>
			<li><a href="/ct2/about-studies">About Studies<img src="/ct2/html/images/pulldown.png" alt="About Studies Menu"></a>
			<ul>
                      <li><a href="/ct2/about-studies/learn">Learn About Studies</a></li>
                      <li><a  href="/ct2/about-studies/other-sites">Other Sites About Studies</a></li>
                      <li><a         href="/ct2/about-studies/glossary">Glossary of Common Site Terms</a></li>
			</ul>
			</li>
			<li><a href="/ct2/manage-recs">Submit Studies<img src="/ct2/html/images/pulldown.png" alt="Submit Studies Menu"></a>
			<ul>
                      <li><a                          href="/ct2/manage-recs/submit-study">Submit Studies to ClinicalTrials.gov PRS</a></li>
                      <li><a                          href="/ct2/manage-recs/background">Why Should I Register and Submit Results?</a></li>
                      <li><a                                href="/ct2/manage-recs/fdaaa">FDAAA 801 and the Final Rule</a></li>
                      <li class="new-group"><a    href="/ct2/manage-recs/how-apply">How to Apply for a PRS Account</a></li>
                      <li><a                        href="/ct2/manage-recs/how-register">How to Register Your Study</a></li>
                      <li><a                         href="/ct2/manage-recs/how-edit">How to Edit Your Study Record</a></li>
                      <li><a                   href="/ct2/manage-recs/how-report">How to Submit Your Results</a></li>
                      <li class="new-group"><a       href="/ct2/manage-recs/faq">Frequently Asked Questions</a></li>
                      <li                  ><a href="/ct2/manage-recs/resources">Support Materials</a></li>
                      <li                  ><a      href="/ct2/manage-recs/present">Training Materials</a></li>
			</ul>
			</li>
			<li><a href="/ct2/resources">Resources<img src="/ct2/html/images/pulldown.png" alt="Resources Menu"></a>
			<ul>
                      <li                  ><a    href="/ct2/resources/pubs">Selected Publications</a></li>
                      <li                  ><a       href="/ct2/resources/alert">Clinical Alerts and Advisories</a></li>
                      <li                  ><a     href="/ct2/resources/rss">RSS Feeds</a></li>
                      <li class="new-group"><a href="/ct2/resources/trends">Trends, Charts, and Maps</a></li>
                      <li                  ><a   href="/ct2/resources/download">Downloading Content for Analysis</a></li>
			</ul>
			</li>
			<li class="last"><a href="/ct2/about-site">About Site<img src="/ct2/html/images/pulldown.png" alt="About Site Menu"></a>
			<ul>
                      <li class="new-group"><a href="/ct2/about-site/new">What's New</a></li>
                      <li                  ><a    href="/ct2/about-site/background">ClinicalTrials.gov Background</a></li>
                      <li                  ><a    href="/ct2/about-site/results">About the Results Database</a></li>
                      <li                  ><a    href="/ct2/about-site/history">History, Policies, and Laws</a></li>
                      <li                  ><a    href="/ct2/about-site/modernization">ClinicalTrials.gov Modernization</a></li>
                      <li                  ><a   href="/ct2/about-site/for-media">Media/Press Resources</a></li>
                      <li class="new-group"><a          href="/ct2/about-site/link-to">Linking to This Site</a></li>
                      <li                  ><a           href="/ct2/about-site/terms-conditions">Terms and Conditions</a></li>
                      <li                  ><a      href="/ct2/about-site/disclaimer">Disclaimer</a></li>
			</ul>
			</li>
			<li><a title="Login to the ClinicalTrials.gov Protocol Registration and Results System (PRS)"
				href="/ct2/manage-recs/register"><span style="border-bottom:1px solid;padding-bottom:1px;padding-right:0;">PRS Login</span></a>
			</li>
								</ul>
				</div>
    		</div>
  		</div>		
		
<div 
style="float:right;margin-top:1.5%;" 
class="w3-hide-small">
	<ul class="sf-menu sf-vertical">
				<li class="first"><a href="/ct2/search/index">Find Studies<img src="/ct2/html/images/pulldown.png" alt="Find Studies Menu"></a>
			<ul>
                      <li                  ><a                  href="/ct2/home">New Search</a></li>
                      <li                  ><a         href="/ct2/search/advanced">Advanced Search</a></li>
                      <li                  ><a     href="/ct2/search/browse?brwse=cond_cat">See Studies by Topic</a></li>
                      <li                  ><a             href="/ct2/search/map">See Studies on Map</a></li>
                      <li class="new-group"><a           href="/ct2/help/how-find/index">How to Search</a></li>
                      <li                  ><a href="/ct2/help/how-use-search-results">How to Use Search Results</a></li>
                      <li                  ><a        href="/ct2/help/how-find/find-study-results">How to Find Results of Studies</a></li>
                      <li                  ><a          href="/ct2/help/how-read-study">How to Read a Study Record</a></li>
			</ul>
			</li>
			<li><a href="/ct2/about-studies">About Studies<img src="/ct2/html/images/pulldown.png" alt="About Studies Menu"></a>
			<ul>
                      <li><a href="/ct2/about-studies/learn">Learn About Studies</a></li>
                      <li><a  href="/ct2/about-studies/other-sites">Other Sites About Studies</a></li>
                      <li><a         href="/ct2/about-studies/glossary">Glossary of Common Site Terms</a></li>
			</ul>
			</li>
			<li><a href="/ct2/manage-recs">Submit Studies<img src="/ct2/html/images/pulldown.png" alt="Submit Studies Menu"></a>
			<ul>
                      <li><a                          href="/ct2/manage-recs/submit-study">Submit Studies to ClinicalTrials.gov PRS</a></li>
                      <li><a                          href="/ct2/manage-recs/background">Why Should I Register and Submit Results?</a></li>
                      <li><a                                href="/ct2/manage-recs/fdaaa">FDAAA 801 and the Final Rule</a></li>
                      <li class="new-group"><a    href="/ct2/manage-recs/how-apply">How to Apply for a PRS Account</a></li>
                      <li><a                        href="/ct2/manage-recs/how-register">How to Register Your Study</a></li>
                      <li><a                         href="/ct2/manage-recs/how-edit">How to Edit Your Study Record</a></li>
                      <li><a                   href="/ct2/manage-recs/how-report">How to Submit Your Results</a></li>
                      <li class="new-group"><a       href="/ct2/manage-recs/faq">Frequently Asked Questions</a></li>
                      <li                  ><a href="/ct2/manage-recs/resources">Support Materials</a></li>
                      <li                  ><a      href="/ct2/manage-recs/present">Training Materials</a></li>
			</ul>
			</li>
			<li><a href="/ct2/resources">Resources<img src="/ct2/html/images/pulldown.png" alt="Resources Menu"></a>
			<ul>
                      <li                  ><a    href="/ct2/resources/pubs">Selected Publications</a></li>
                      <li                  ><a       href="/ct2/resources/alert">Clinical Alerts and Advisories</a></li>
                      <li                  ><a     href="/ct2/resources/rss">RSS Feeds</a></li>
                      <li class="new-group"><a href="/ct2/resources/trends">Trends, Charts, and Maps</a></li>
                      <li                  ><a   href="/ct2/resources/download">Downloading Content for Analysis</a></li>
			</ul>
			</li>
			<li class="last"><a href="/ct2/about-site">About Site<img src="/ct2/html/images/pulldown.png" alt="About Site Menu"></a>
			<ul>
                      <li class="new-group"><a href="/ct2/about-site/new">What's New</a></li>
                      <li                  ><a    href="/ct2/about-site/background">ClinicalTrials.gov Background</a></li>
                      <li                  ><a    href="/ct2/about-site/results">About the Results Database</a></li>
                      <li                  ><a    href="/ct2/about-site/history">History, Policies, and Laws</a></li>
                      <li                  ><a    href="/ct2/about-site/modernization">ClinicalTrials.gov Modernization</a></li>
                      <li                  ><a   href="/ct2/about-site/for-media">Media/Press Resources</a></li>
                      <li class="new-group"><a          href="/ct2/about-site/link-to">Linking to This Site</a></li>
                      <li                  ><a           href="/ct2/about-site/terms-conditions">Terms and Conditions</a></li>
                      <li                  ><a      href="/ct2/about-site/disclaimer">Disclaimer</a></li>
			</ul>
			</li>
			<li><a title="Login to the ClinicalTrials.gov Protocol Registration and Results System (PRS)"
				href="/ct2/manage-recs/register"><span style="border-bottom:1px solid;padding-bottom:1px;padding-right:0;">PRS Login</span></a>
			</li>
				</ul>
    <div style="clear:both;"></div>
</div>
<div style="clear:both;"></div>

</div> 
<div class="ct-outer_breadcrumb w3-container">
	<div id="breadcrumb">
    <ul class="ct-horz-list w3-left">
			<li><a href="/ct2/home">Home</a></li>
												<li><a href="/ct2/results">Search Results</a></li>
										<li>Study Record Detail</li>
    </ul>
    <div id="savedStudies" class="w3-right">
  	<div id="cart" style="cursor:pointer;" onclick="location.href=('/ct2/results'+cartToURL()); showWorking();">
  	<button class="ct-savedStudiesEnabled" id="open-cart-link" type="button" 
  		onclick="location.href=('/ct2/results'+cartToURL()); showWorking();"
  		title="Show previously saved studies.">Saved Studies</button>
  	</div>
</div>
<script type="text/javascript" src="/ct2/html/js/cart.js?v=44"></script><noscript></noscript>

		<script type="text/javascript">
	$(document).ready(function(){
		$("input#saved").prop( 'checked', (inCart("NCT02795767")>=0));
	});
</script>
		<div class="w3-right" style="margin-right: 1em;">
			<label for="saved" title="Add or Remove this study in the Saved Studies list"><input type="checkbox" id="saved" name="NCT02795767" onchange="updateCart('NCT02795767');" style="margin-left:1em;"> Save this study </label>
		</div>
		<div id="maxSavedStudies-popup" class="w3-modal" style="cursor:pointer;border:2px groove" onclick="$('#maxSavedStudies-popup').hide();">
	<div id="maxSavedStudies-popup-content" class="w3-modal-content">
		<div class="w3-display-container" style="border:1px solid #ccc;background-color:#eee;">
			<form>
			<div class="w3-center" style="font-size:large;font-weight:bold;padding:3ex 1.5em;">
				<img src="/ct2/html/images/warning.png" alt="Maximum Saved Studies Reached" style="max-width:1.0rem;cursor:pointer;"/>
			    <b>Warning</b>
				<div style="margin-top:1ex;margin-bottom:0.5ex;">You have reached the maximum number of saved studies (100).</div>
				<div>Please remove one or more studies before adding more.</div>
			</div>
		
			<div class="w3-center" style="padding-bottom:1.5ex">
			  <input class="ct-searchButton" type="button" style="opacity:1.0;font-weight:bold;font-size:inherit;padding:1.1ex 1em;" onclick="$('#maxSavedStudies-popup').hide();" value="Close" title="Close this dialog"/>
			</div>
			</form>
		</div>
	</div>
</div>

	</div>
</div>

<div style="clear:both;"></div>

<div id="main-content" tabindex='-1'>
	
	
		<div class="tr-indent2">
        	<h1 class="tr-h1 ct-sans-serif tr-solo_record">A Study of Emicizumab Administered Subcutaneously (SC) in Pediatric Participants With Hemophilia A and Factor VIII (FVIII) Inhibitors (HAVEN 2)</h1>

  <div class="w3-row">
    <div class="w3-col m6">       <div class="usa-alert usa-alert-warning" style="clear:both;margin:2ex 2em;">
        <table>
          <tr>
            <td style="width:5%">
              <img src="/ct2/html/images/warning.png" style="width:1.3em;" alt=""/>
            </td>
            <td style="padding-right:2em;">
              The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government.
                            Read our <a href="/ct2/about-site/disclaimer">disclaimer</a> for details.
            </td>
          </tr>
        </table>
      </div>      </div> 
<!--
  <div style="float:right;margin-right:4em">ClinicalTrials.gov Identifier: NCT02795767</div>
-->
  <div class="w3-col m1">&nbsp;</div> 
  <div class="w3-col m5">   <table style="width:95%">
  <tr><td>ClinicalTrials.gov Identifier: NCT02795767</td>
  </tr>
  <tr><td>
      
       
              <div  class="tr-status tr-not-recruiting-colors" >
                        <span style="display:inline;" class="term" data-term="Recruitment Status" title="Show definition">Recruitment Status <i class="fa fa-info-circle term" aria-hidden="true" data-term="Recruitment Status" style="border-bottom-style:none;"></i></span> : 
                    Completed
                  
                
  <div style="font-size:inherit">
  <span style="display:inline;" class="term" data-term="First Posted" title="Show definition">First Posted <i class="fa fa-info-circle term" aria-hidden="true" data-term="First Posted" style="border-bottom-style:none;"></i></span> : June 10, 2016</div>
      <div style="font-size:inherit">
    <span style="display:inline;" class="term" data-term="Results First Posted" title="Show definition">Results First Posted <i class="fa fa-info-circle term" aria-hidden="true" data-term="Results First Posted" style="border-bottom-style:none;"></i></span> : April 10, 2019</div>
    <div style="font-size:inherit">
  <span style="display:inline;" class="term" data-term="Last Update Posted" title="Show definition">Last Update Posted <i class="fa fa-info-circle term" aria-hidden="true" data-term="Last Update Posted" style="border-bottom-style:none;"></i></span> : June 2, 2021</div>

  
      </div>
  </td>
  </tr>
  </table>
  </div>
  </div>


                <div class="tr-info-title">Sponsor:</div>
                <div class="tr-info-text" id="sponsor"> Hoffmann-La Roche </div>
                <div class="tr-info-title">Collaborator:</div>
                                  				  				                                    <div class="tr-info-text" id="sponsor1">Chugai Pharmaceutical</div> 
                  				  
                              <div class="tr-info-title">Information provided by (Responsible Party):</div>
                <div class="tr-info-text" id="responsibleparty">Hoffmann-La Roche</div>
              	</div>
<br>


<div id="tabs">
    <ul id="tab-links">
		<li id="full-text"  class="current">Study Details     </li>
		<li id="tabular"   ><a href="/ct2/show/record/NCT02795767" >Tabular View</a></li>
  					<li id="results"   ><a href="/ct2/show/results/NCT02795767">Study Results</a></li>
						<li id="disclaimer"><a title="Disclaimer - opens new window"  href="/ct2/about-site/disclaimer" onclick="openNewWindow('/ct2/about-site/disclaimer'); return false"
>Disclaimer</a></li>
		<li id="howtoread"><a title="How to Read a Study Record - opens new window"  href="/ct2/help/how-read-study" onclick="openNewWindow('/ct2/help/how-read-study'); return false"
>How to Read a Study Record</a></li>
    </ul>
</div>  <!--
<div style="background-color:#f6f6f6;margin-top:5.0ex;padding-bottom:1.5ex;"> </div>
-->
		
	<div id="tab-body">
		<div class="tr-indent2" style="background-color:white;">
						  
<!-- purpose_section -->
<div class="tr-indent1" style="margin-top:1ex">

<div class="tr-subsection">
	<div class="ct-header2"><a id="studydesc"></a>Study Description</div>
	<div class="tr-underline"></div>
	<div class="tr-dropdown" style="padding-right:10em">
Go&nbsp;to&nbsp;
<button class="tr-dropbtn" style="font-weight:bold; font-size:14px">
<img src="/ct2/html/images/pulldown.png" alt="sections">
</button>

  <div class="tr-dropdown-content">
	<a href="#wrapper">Top of Page</a>
    <a href="#studydesc">Study Description</a>
    <a href="#studydesign">Study Design</a>

    <!-- arms and groups table -->
        <a href="#armgroup">Arms and Interventions</a>
    
        <a href="#outcomemeasures">Outcome Measures</a>
        <a href="#eligibility">Eligibility Criteria</a>
    <a href="#contactlocation">Contacts and Locations</a>
    <a href="#moreinfo">More Information</a>
  </div>
</div>
</div>

<div class="tr-indent2" style="margin-top:2ex">

  <div class="ct-body3">Brief Summary:</div>
  <div class="ct-body3 tr-indent2">This non-randomized, multicenter, open-label, Phase III clinical study will evaluate the efficacy, safety, and pharmacokinetics of emicizumab administered subcutaneously initially once weekly (QW) in pediatric participants with hemophilia A with FVIII inhibitors. This study will open two additional non-randomized cohorts to investigate once every 2 weeks (Q2W) and once every 4 weeks (Q4W) regimens in pediatric participants.</div><br/>

    <!-- condition, intervention, phase summary table -->
  <table class="ct-data_table tr-data_table" border="1" style="margin:auto;width:80%;">
    <tr style="text-align:left;">
            <th class="ct-header3 tr-pale_banner_color">
<span style="display:inline;" class="term" data-term="Condition/disease" title="Show definition">Condition or disease <i class="fa fa-info-circle term" aria-hidden="true" data-term="Condition/disease" style="border-bottom-style:none;"></i></span>       </th>
                  <th class="ct-header3 tr-pale_banner_color">
<span style="display:inline;" class="term" data-term="Intervention/treatment" title="Show definition">Intervention/treatment <i class="fa fa-info-circle term" aria-hidden="true" data-term="Intervention/treatment" style="border-bottom-style:none;"></i></span>       </th>
                  <th class="ct-header3 tr-pale_banner_color">
<span style="display:inline;" class="term" data-term="Phase" title="Show definition">Phase <i class="fa fa-info-circle term" aria-hidden="true" data-term="Phase" style="border-bottom-style:none;"></i></span>       </th>
          </tr>
    <tr style="text-align:left;vertical-align:top;">
            <td class="ct-body3">
                <span style="display:block;margin-bottom:1ex;">Hemophilia A</span>
              </td>
                  <td class="ct-body3">
                <span style="display:block;margin-bottom:1ex;">Drug: Emicizumab</span>
              </td>
                  <td class="ct-body3" style="white-space:nowrap;">
                <span style="display:block;margin-bottom:1ex;">Phase 3</span>
              </td>
          </tr>
  </table>
  <br/>
  
      <span style="display:inline;" class="term" data-term="Expanded Access" title="Show definition">Expanded Access <i class="fa fa-info-circle term" aria-hidden="true" data-term="Expanded Access"></i></span>: An investigational treatment associated with this study has been <span style="color:green">approved</span> for sale to the public. &nbsp;
          <a class="ct-header3 tr-tr-study-link" title="Show expanded access study" href="/ct2/show/NCT03154437" 
      onclick="openPopupWindow('/ct2/show/NCT03154437',false); return false;">More info ...</a>
        <br/>
    <br/>
  
  </div> 
<div class="tr-subsection">
  <div class="ct-header2"><a id="studydesign"></a>Study Design</div>
  <div class="tr-underline"></div>
  <div class="tr-dropdown" style="padding-right:10em">
Go&nbsp;to&nbsp;
<button class="tr-dropbtn" style="font-weight:bold; font-size:14px">
<img src="/ct2/html/images/pulldown.png" alt="sections">
</button>

  <div class="tr-dropdown-content">
	<a href="#wrapper">Top of Page</a>
    <a href="#studydesc">Study Description</a>
    <a href="#studydesign">Study Design</a>

    <!-- arms and groups table -->
        <a href="#armgroup">Arms and Interventions</a>
    
        <a href="#outcomemeasures">Outcome Measures</a>
        <a href="#eligibility">Eligibility Criteria</a>
    <a href="#contactlocation">Contacts and Locations</a>
    <a href="#moreinfo">More Information</a>
  </div>
</div>
</div>

  <p>
  <table class="ct-layout_table tr-tableStyle tr-studyInfo" style="margin-bottom:2ex;">
   <caption>Layout table for study information</caption>
   <thead>
    <tr>
      <th id="studyInfoColTitle"></th>
      <th id="studyInfoColData"></th>
    </tr>
    </thead>
    <tbody>
        <tr>
      <td headers="studyInfoColTitle">
<span style="display:inline;" class="term" data-term="Study Type" title="Show definition">Study Type <i class="fa fa-info-circle term" aria-hidden="true" data-term="Study Type" style="border-bottom-style:none;"></i></span> :</td>
      <td headers="studyInfoColData" style="padding-left:1em">
        Interventional
                &nbsp;(Clinical Trial)
                
        
      </td>
    </tr>
                    <tr>
      <td headers="studyInfoColTitle">Actual
<span style="display:inline;" class="term" data-term="Enrollment" title="Show definition">Enrollment <i class="fa fa-info-circle term" aria-hidden="true" data-term="Enrollment" style="border-bottom-style:none;"></i></span> :</td>
      <td headers="studyInfoColData" style="padding-left:1em">88 participants</td>
    </tr>
                <tr>
            <td headers="studyInfoColTitle">Allocation:</td>
            <td headers="studyInfoColData" style="padding-left:1em">Non-Randomized</td>
    </tr>
        <tr>
            <td headers="studyInfoColTitle">Intervention Model:</td>
            <td headers="studyInfoColData" style="padding-left:1em">Parallel Assignment</td>
    </tr>
        <tr>
            <td headers="studyInfoColTitle">Masking:</td>
            <td headers="studyInfoColData" style="padding-left:1em"> None (Open Label)</td>
    </tr>
        <tr>
            <td headers="studyInfoColTitle">Primary Purpose:</td>
            <td headers="studyInfoColData" style="padding-left:1em"> Treatment</td>
    </tr>
                    <tr>
<!--
      <td headers="studyInfoColTitle" style="padding-top:2ex;">Official Title:</td>
-->
      <td headers="studyInfoColTitle">Official Title:</td>
      <td headers="studyInfoColData" style="padding-left:1em;">A Multicenter, Open-Label, Phase III Clinical Trial to Evaluate the Efficacy, Safety, and Pharmacokinetics of Subcutaneous Administration of Emicizumab in Hemophilia A Pediatric Patients With Inhibitors</td>
    </tr>
    
            <tr>
        <td headers="studyInfoColTitle">  Actual <span style="display:inline;" class="term" data-term="Study Start Date" title="Show definition">Study Start Date <i class="fa fa-info-circle term" aria-hidden="true" data-term="Study Start Date" style="border-bottom-style:none;"></i></span> :</td>
        <td headers="studyInfoColData" style="padding-left:1em">July 22, 2016</td>
      </tr>
                  <tr>
        <td headers="studyInfoColTitle">  Actual <span style="display:inline;" class="term" data-term="Primary Completion Date" title="Show definition">Primary Completion Date <i class="fa fa-info-circle term" aria-hidden="true" data-term="Primary Completion Date" style="border-bottom-style:none;"></i></span> :</td>
        <td headers="studyInfoColData" style="padding-left:1em">April 30, 2018</td>
      </tr>
                  <tr>
        <td headers="studyInfoColTitle">  Actual <span style="display:inline;" class="term" data-term="Study Completion Date" title="Show definition">Study Completion Date <i class="fa fa-info-circle term" aria-hidden="true" data-term="Study Completion Date" style="border-bottom-style:none;"></i></span> :</td>
        <td headers="studyInfoColData" style="padding-left:1em">November 11, 2020</td>
      </tr>
            </tbody>
    </table>

    <!-- NLM links -->
<p>
<div class="tr-indent2">
  <div class="usa-alert usa-alert-warning nlm-info">
    <strong>Resource links provided by the National Library of Medicine</strong>
    <img src="/ct2/html/images/NIH_NLM_ABRV_BLK_4.png" style="width:5em; float:right;" alt=""/>
    <p>
    <p>

    <!-- ghr links -->
  <div style="margin-bottom:2ex">
    <a class="tr-study-link" href="https://medlineplus.gov/genetics/" title="MedlinePlus Genetics" onclick="openNewWindow('https://medlineplus.gov/genetics/'); return false">MedlinePlus Genetics</a> related topics:
    	    	    	<a class="tr-study-link" style="margin-left:0.5em;" href="https://medlineplus.gov/genetics/condition/hemophilia" title="Hemophilia at Genetics Home Reference" onclick="openNewWindow('https://medlineplus.gov/genetics/condition/hemophilia'); return false">Hemophilia</a>
	          </div>
  
    <!-- medline links -->
  <div style="margin-bottom:2ex;">
    <a class="tr-study-link" href="https://medlineplus.gov/" title="MedlinePlus" onclick="openNewWindow('https://medlineplus.gov/'); return false">MedlinePlus</a> related topics:
    	    	    	<a class="tr-study-link" style="margin-left:0.5em;" href="https://medlineplus.gov/hemophilia.html" title="Hemophilia at MedlinePlus" onclick="openNewWindow('https://medlineplus.gov/hemophilia.html'); return false">Hemophilia</a>
	          </div>
  
    <!-- SIS links -->
  <div style="margin-bottom:2ex;">
    <a class="tr-study-link" href="https://druginfo.nlm.nih.gov/drugportal" title="Drug Information Portal" onclick="openNewWindow('https://druginfo.nlm.nih.gov/drugportal'); return false">Drug Information</a> available for:
    	    	    	<a class="tr-study-link" style="margin-left:0.5em;" href="https://druginfo.nlm.nih.gov/drugportal/name/Emicizumab" title="Emicizumab at Drug Information Portal" onclick="openNewWindow('https://druginfo.nlm.nih.gov/drugportal/name/Emicizumab'); return false">Emicizumab</a>
	          </div>
  
    <!-- ORD links -->
  <div style="margin-bottom:2ex;">
    <a class="tr-study-link" href="https://rarediseases.info.nih.gov/gard" title="Genetic and Rare Diseases Information Center" onclick="openNewWindow('https://rarediseases.info.nih.gov/gard'); return false">Genetic and Rare Diseases Information Center</a> resources:
    	    	    	<a class="tr-study-link" style="margin-left:0.5em;" href="https://rarediseases.info.nih.gov/diseases/10418/hemophilia" title="Hemophilia at Genetic and Rare Diseases Information Center" onclick="openNewWindow('https://rarediseases.info.nih.gov/diseases/10418/hemophilia'); return false">Hemophilia</a>
	        	    	    	<a class="tr-study-link" style="margin-left:0.5em;" href="https://rarediseases.info.nih.gov/diseases/6591/hemophilia-a" title="Hemophilia&#160;A at Genetic and Rare Diseases Information Center" onclick="openNewWindow('https://rarediseases.info.nih.gov/diseases/6591/hemophilia-a'); return false">Hemophilia&#160;A</a>
	          </div>
  
  
  <!-- Ropr Link -->
<!-- Commented out RoPR
  -->

  <div style="margin-bottom:2ex;">
  <a class="tr-study-link" href="/ct2/info/fdalinks" title="Show FDA resources page" onclick="openNewWindow('/ct2/info/fdalinks'); return false">U.S. FDA Resources</a>
  </div>

  </div>
</div>


  
  <br/>
    </div>

    <!-- arms and groups table -->
    		<div class="tr-subsection">
		    		    	<div class="ct-header2"><a id="armgroup"></a>Arms and Interventions</div>
		    		    <div class="tr-underline"></div>
			<div class="tr-dropdown" style="padding-right:10em">
Go&nbsp;to&nbsp;
<button class="tr-dropbtn" style="font-weight:bold; font-size:14px">
<img src="/ct2/html/images/pulldown.png" alt="sections">
</button>

  <div class="tr-dropdown-content">
	<a href="#wrapper">Top of Page</a>
    <a href="#studydesc">Study Description</a>
    <a href="#studydesign">Study Design</a>

    <!-- arms and groups table -->
        <a href="#armgroup">Arms and Interventions</a>
    
        <a href="#outcomemeasures">Outcome Measures</a>
        <a href="#eligibility">Eligibility Criteria</a>
    <a href="#contactlocation">Contacts and Locations</a>
    <a href="#moreinfo">More Information</a>
  </div>
</div>
		</div>
	
    <div style="padding-left:.8em; padding-right:1.2em;text-align:left;">
        <p>
    <table class="ct-data_table tr-data_table" style="padding:5px;width:100%;border-width:1px;">
      <thead>
      <tr style="text-align:left;">
        <th class="ct-header3 tr-pale_banner_color" style="width:50%;">
            				<span style="display:inline;" class="term" data-term="Arm" title="Show definition">Arm <i class="fa fa-info-circle term" aria-hidden="true" data-term="Arm" style="border-bottom-style:none;"></i></span> 			        </th>
                <th class="ct-header3 tr-pale_banner_color">
			<span style="display:inline;" class="term" data-term="Intervention/treatment" title="Show definition">Intervention/treatment <i class="fa fa-info-circle term" aria-hidden="true" data-term="Intervention/treatment" style="border-bottom-style:none;"></i></span>         </th>
              </tr>
      </thead>
      <tbody>
            <tr style="text-align:left;vertical-align:top;">
        <td class="ct-body3">
          Experimental: Cohort A: 1.5 mg/kg Emicizumab QW
<div class="tr-indent2" style="margin-top:0.5ex">Participants will receive emicizumab at a loading dose of 3 milligrams per kilogram (mg/kg) QW SC for the first 4 weeks followed by a maintenance dose of 1.5 mg/kg QW SC for a minimum of 52 weeks, or until unacceptable toxicity, discontinuation from the study due to any cause, or other criteria set forth in the protocol, whichever occurs first.</div>
        </td>
                <td class="ct-body3">
                      Drug: Emicizumab
<div class="tr-indent2" style="margin-top:0.5ex">Emicizumab will be administered as per the schedule specified in the respective arm.</div>
<div class="tr-indent2" style="margin-top:0.5ex">Other Names:<ul style="margin-top:0.5ex">
<li>Hemlibra</li>
<li>RO5534262</li>
<li>RG6013</li>
<li>ACE910</li>
</ul>
</div><br/>
                  </td>
              </tr>
            <tr style="text-align:left;vertical-align:top;">
        <td class="ct-body3">
          Experimental: Cohort B: 3 mg/kg Emicizumab Q2W
<div class="tr-indent2" style="margin-top:0.5ex">Participants will receive emicizumab at a loading dose of 3 mg/kg QW SC for the first 4 weeks followed by a maintenance dose of 3 mg/kg every 2 weeks (Q2W) SC for a minimum of 52 weeks, or until unacceptable toxicity, discontinuation from the study due to any cause, or other criteria set forth in the protocol, whichever occurs first.</div>
        </td>
                <td class="ct-body3">
                      Drug: Emicizumab
<div class="tr-indent2" style="margin-top:0.5ex">Emicizumab will be administered as per the schedule specified in the respective arm.</div>
<div class="tr-indent2" style="margin-top:0.5ex">Other Names:<ul style="margin-top:0.5ex">
<li>Hemlibra</li>
<li>RO5534262</li>
<li>RG6013</li>
<li>ACE910</li>
</ul>
</div><br/>
                  </td>
              </tr>
            <tr style="text-align:left;vertical-align:top;">
        <td class="ct-body3">
          Experimental: Cohort C: 6 mg/kg Emicizumab Q4W
<div class="tr-indent2" style="margin-top:0.5ex">Participants will receive emicizumab at a loading dose of 3 mg/kg QW SC for the first 4 weeks followed by a maintenance dose of 6 mg/kg every 4 weeks (Q4W) SC for a minimum of 52 weeks, or until unacceptable toxicity, discontinuation from the study due to any cause, or other criteria set forth in the protocol, whichever occurs first.</div>
        </td>
                <td class="ct-body3">
                      Drug: Emicizumab
<div class="tr-indent2" style="margin-top:0.5ex">Emicizumab will be administered as per the schedule specified in the respective arm.</div>
<div class="tr-indent2" style="margin-top:0.5ex">Other Names:<ul style="margin-top:0.5ex">
<li>Hemlibra</li>
<li>RO5534262</li>
<li>RG6013</li>
<li>ACE910</li>
</ul>
</div><br/>
                  </td>
              </tr>
            </tbody>
    </table>
          </div>
    <br/>

    
    <!-- more details -->
  <br/>
  <div class="tr-subsection">
	  <div class="ct-header2"><a id="outcomemeasures"></a>Outcome Measures</div>
	  <div class="tr-underline"></div>
	  <div class="tr-dropdown" style="padding-right:10em">
Go&nbsp;to&nbsp;
<button class="tr-dropbtn" style="font-weight:bold; font-size:14px">
<img src="/ct2/html/images/pulldown.png" alt="sections">
</button>

  <div class="tr-dropdown-content">
	<a href="#wrapper">Top of Page</a>
    <a href="#studydesc">Study Description</a>
    <a href="#studydesign">Study Design</a>

    <!-- arms and groups table -->
        <a href="#armgroup">Arms and Interventions</a>
    
        <a href="#outcomemeasures">Outcome Measures</a>
        <a href="#eligibility">Eligibility Criteria</a>
    <a href="#contactlocation">Contacts and Locations</a>
    <a href="#moreinfo">More Information</a>
  </div>
</div>
  </div>
  <br/>
  <div class="tr-indent3" style="margin-right:1em;">

        <!-- primary outcomes -->
    <div class="ct-body3">
<span style="display:inline;" class="term" data-term="Primary Outcome Measure" title="Show definition">Primary Outcome Measures <i class="fa fa-info-circle term" aria-hidden="true" data-term="Primary Outcome Measure" style="border-bottom-style:none;"></i></span> :
      <ol style="margin-top:1ex; margin-bottom:1ex;">
            	<li style="margin-top:0.7ex;">Cohort A: Model-Based Annualized Bleed Rate (ABR) for Treated Bleeds in Treated Participants &lt;12 Years of Age [&nbsp;Time&nbsp;Frame:&nbsp;From Baseline to 52 weeks; At the primary completion date, the median (min-max) duration of the efficacy period in Cohort A was 57.57 (17.9-92.6) weeks.&nbsp;]<div class="tr-indent2" style="margin-top:1ex;">The number of treated bleeds over the efficacy period is presented here as a model-based ABR that was analyzed using a negative binomial regression model with efficacy period as an offset to account for the difference in follow-up times. A bleed is considered a &quot;treated bleed&quot; if it is directly followed (i.e., no intervening bleed) by a hemophilia medication reported to be a &quot;treatment for bleed&quot;, irrespective of time between treatment and the preceding bleed. A bleed and the first treatment thereafter and before a new bleed starts, are considered to be pairs, with the following exception: if multiple bleeds occur on the same calendar day, the subsequent treatment is considered to apply for each of these multiple bleeds. The 72-hour rule was implemented: two bleeds of the same type and at the same anatomical location are counted as one bleed if the second bleed occurs within 72 hours from the last treatment for the first bleed. Bleeds due to surgery/procedure are excluded.</div><br/>
            	<li style="margin-top:0.7ex;">Cohort A: Model-Based Annualized Bleed Rate (ABR) for All Bleeds in Treated Participants &lt;12 Years of Age [&nbsp;Time&nbsp;Frame:&nbsp;From Baseline to 52 weeks; At the primary completion date, the median (min-max) duration of the efficacy period in Cohort A was 57.57 (17.9-92.6) weeks.&nbsp;]<div class="tr-indent2" style="margin-top:1ex;">The number of all bleeds over the efficacy period is presented here as a model-based ABR that was analyzed using a negative binomial regression model with efficacy period as an offset to account for the difference in followup times (i.e., the time that each participant stays in the study). In this outcome measure, all bleeds are included, irrespective of treatment with coagulation factors, with the following exception: bleeds due to surgery/procedure are excluded. As &quot;all bleeds&quot; comprises both treated and non-treated bleeds, the 72-hour rule was implemented separately for treated and non-treated bleeds. For treated bleeds, the 72-hour rule was implemented exactly as defined for the &quot;treated bleeds&quot; outcome measure. For non-treated bleeds, the 72-hour rule was implemented by calculating a treatment-free period of 72 hours from the bleed itself.</div><br/>
            	<li style="margin-top:0.7ex;">Cohort A: Model-Based Annualized Bleed Rate (ABR) for Treated Spontaneous Bleeds in Treated Participants &lt;12 Years of Age [&nbsp;Time&nbsp;Frame:&nbsp;From Baseline to 52 weeks; At the primary completion date, the median (min-max) duration of the efficacy period in Cohort A was 57.57 (17.9-92.6) weeks.&nbsp;]<div class="tr-indent2" style="margin-top:1ex;">The number of treated spontaneous bleeds over the efficacy period is presented here as a model-based ABR that was analyzed using a negative binomial regression model with efficacy period as an offset to account for the difference in follow-up times (i.e., the time that each participant stays in the study). A bleed is classified as &quot;spontaneous&quot; if there is no other known contributing factor such as trauma or procedure/surgery. A &quot;treated spontaneous bleed&quot; is a spontaneous bleed that also fulfills the conditions of a treated bleed (see ABR for Treated Bleeds for the definition). Treated bleeds that fulfilled the 72-hour rule were included in the analysis of spontaneous bleeds. Bleeds due to surgery/procedure are excluded.</div><br/>
            	<li style="margin-top:0.7ex;">Cohort A: Model-Based Annualized Bleed Rate (ABR) for Treated Joint Bleeds in Treated Participants &lt;12 Years of Age [&nbsp;Time&nbsp;Frame:&nbsp;From Baseline to 52 weeks; At the primary completion date, the median (min-max) duration of the efficacy period in Cohort A was 57.57 (17.9-92.6) weeks.&nbsp;]<div class="tr-indent2" style="margin-top:1ex;">The number of treated joint bleeds over the efficacy period is presented here as a model-based ABR that was analyzed using a negative binomial regression model with efficacy period as an offset to account for the difference in follow-up times (i.e., the time that each participant stays in the study). A &quot;joint bleed&quot; is defined as a bleed with type reported as &quot;joint&quot; and with at least one of the following symptoms: increasing swelling or warmth of the skin over the joint and/or increasing pain, decreased range of motion, or difficulty using the joint compared with baseline. A &quot;treated joint bleed&quot; is a joint bleed that also fulfills the conditions of a treated bleed (see ABR for Treated Bleeds for the definition). Only treated bleeds that fulfilled the 72-hour rule were included in the analysis of treated joint bleeds, excluding bleeds due to surgery/procedure.</div><br/>
            	<li style="margin-top:0.7ex;">Cohort A: Model-Based Annualized Bleed Rate (ABR) for Treated Target Joint Bleeds in Treated Participants &lt;12 Years of Age [&nbsp;Time&nbsp;Frame:&nbsp;From Baseline to 52 weeks; At the primary completion date, the median (min-max) duration of the efficacy period in Cohort A was 57.57 (17.9-92.6) weeks.&nbsp;]<div class="tr-indent2" style="margin-top:1ex;">The number of treated target joint bleeds over the efficacy period is presented here as a model-based ABR that was analyzed using a negative binomial regression model with efficacy period as an offset to account for the difference in follow-up times (i.e., the time that each participant stays in the study). A &quot;target joint bleed&quot; is defined as a joint bleed in a target joint, which is a joint location where at least 3 bleeds have occurred over the last 24 weeks prior to study entry. A &quot;treated target joint bleed&quot; is a target joint bleed that also fulfills the conditions of a treated bleed (see ABR for Treated Bleeds for the definition). Bleeds due to surgery/procedure are excluded.</div><br/>
            	<li style="margin-top:0.7ex;">Cohort A: Mean Calculated Annualized Bleed Rate (ABR) for Treated Bleeds in Treated Participants &lt;12 Years of Age [&nbsp;Time&nbsp;Frame:&nbsp;From Baseline to 52 weeks; At the primary completion date, the median (min-max) duration of the efficacy period in Cohort A was 57.57 (17.9-92.6) weeks.&nbsp;]<div class="tr-indent2" style="margin-top:1ex;">The number of treated bleeds over the efficacy period is presented here as a calculated ABR that was annualized for each participant using the following formula: ABR = (number of bleeds/number of days during the efficacy period) x 365.25. A bleed is considered a &quot;treated bleed&quot; if it is directly followed (i.e., no intervening bleed) by a hemophilia medication reported to be a &quot;treatment for bleed&quot;, irrespective of time between treatment and the preceding bleed. A bleed and the first treatment thereafter and before a new bleed starts, are considered to be pairs, with the following exception: if multiple bleeds occur on the same calendar day, the subsequent treatment is considered to apply for each of these multiple bleeds. The 72-hour rule was implemented: two bleeds of the same type and at the same anatomical location are counted as one bleed if the second bleed occurs within 72 hours from the last treatment for the first bleed. Bleeds due to surgery/procedure are excluded.</div><br/>
            	<li style="margin-top:0.7ex;">Cohort A: Mean Calculated Annualized Bleed Rate (ABR) for All Bleeds in Treated Participants &lt;12 Years of Age [&nbsp;Time&nbsp;Frame:&nbsp;From Baseline to 52 weeks; At the primary completion date, the median (min-max) duration of the efficacy period in Cohort A was 57.57 (17.9-92.6) weeks.&nbsp;]<div class="tr-indent2" style="margin-top:1ex;">The number of all bleeds over the efficacy period is presented here as a calculated ABR that was annualized for each participant using the following formula: ABR = (number of bleeds/number of days during the efficacy period) x 365.25. In this outcome measure, all bleeds are included, irrespective of treatment with coagulation factors, with the following exception: bleeds due to surgery/procedure are excluded. As &quot;all bleeds&quot; comprises both treated and non-treated bleeds, the 72-hour rule was implemented separately for treated and non-treated bleeds. For treated bleeds, the 72-hour rule was implemented exactly as defined for the &quot;treated bleeds&quot; outcome measure. For non-treated bleeds, the 72-hour rule was implemented by calculating a treatment-free period of 72 hours from the bleed itself.</div><br/>
            	<li style="margin-top:0.7ex;">Cohort A: Mean Calculated Annualized Bleed Rate (ABR) for Treated Spontaneous Bleeds in Treated Participants &lt;12 Years of Age [&nbsp;Time&nbsp;Frame:&nbsp;From Baseline to 52 weeks; At the primary completion date, the median (min-max) duration of the efficacy period in Cohort A was 57.57 (17.9-92.6) weeks.&nbsp;]<div class="tr-indent2" style="margin-top:1ex;">The number of treated spontaneous bleeds over the efficacy period is presented here as a calculated ABR that was annualized for each participant using the following formula: ABR = (number of bleeds/number of days during the efficacy period) x 365.25. A bleed is classified as &quot;spontaneous&quot; if there is no other known contributing factor such as trauma or procedure/surgery. A &quot;treated spontaneous bleed&quot; is a spontaneous bleed that also fulfills the conditions of a treated bleed (see ABR for Treated Bleeds for the definition). Treated bleeds that fulfilled the 72-hour rule were included in the analysis of spontaneous bleeds. Bleeds due to surgery/procedure are excluded.</div><br/>
            	<li style="margin-top:0.7ex;">Cohort A: Mean Calculated Annualized Bleed Rate (ABR) for Treated Joint Bleeds in Treated Participants &lt;12 Years of Age [&nbsp;Time&nbsp;Frame:&nbsp;From Baseline to 52 weeks; At the primary completion date, the median (min-max) duration of the efficacy period in Cohort A was 57.57 (17.9-92.6) weeks.&nbsp;]<div class="tr-indent2" style="margin-top:1ex;">The number of treated joint bleeds over the efficacy period is presented here as a calculated ABR that was annualized for each participant using the following formula: ABR = (number of bleeds/number of days during the efficacy period) x 365.25. A &quot;joint bleed&quot; is defined as a bleed with type reported as &quot;joint&quot; and with at least one of the following symptoms: increasing swelling or warmth of the skin over the joint and/or increasing pain, decreased range of motion, or difficulty using the joint compared with baseline. A &quot;treated joint bleed&quot; is a joint bleed that also fulfills the conditions of a treated bleed (see ABR for Treated Bleeds for the definition). Only treated bleeds that fulfilled the 72-hour rule were included in the analysis of treated joint bleeds, excluding bleeds due to surgery/procedure.</div><br/>
            	<li style="margin-top:0.7ex;">Cohort A: Mean Calculated Annualized Bleed Rate (ABR) for Treated Target Joint Bleeds in Treated Participants &lt;12 Years of Age [&nbsp;Time&nbsp;Frame:&nbsp;From Baseline to 52 weeks; At the primary completion date, the median (min-max) duration of the efficacy period in Cohort A was 57.57 (17.9-92.6) weeks.&nbsp;]<div class="tr-indent2" style="margin-top:1ex;">The number of treated target joint bleeds over the efficacy period is presented here as a calculated ABR that was annualized for each participant using the following formula: ABR = (number of bleeds/number of days during the efficacy period) x 365.25. A &quot;target joint bleed&quot; is defined as a joint bleed in a target joint, which is a joint location where at least 3 bleeds have occurred over the last 24 weeks prior to study entry. A &quot;treated target joint bleed&quot; is a target joint bleed that also fulfills the conditions of a treated bleed (see ABR for Treated Bleeds for the definition). Bleeds due to surgery/procedure are excluded.</div><br/>
            	<li style="margin-top:0.7ex;">Cohort A: Median Calculated Annualized Bleed Rate (ABR) for Treated Bleeds in Treated Participants &lt;12 Years of Age [&nbsp;Time&nbsp;Frame:&nbsp;From Baseline to 52 weeks; At the primary completion date, the median (min-max) duration of the efficacy period in Cohort A was 57.57 (17.9-92.6) weeks.&nbsp;]<div class="tr-indent2" style="margin-top:1ex;">The number of treated bleeds over the efficacy period is presented here as a calculated ABR that was annualized for each participant using the following formula: ABR = (number of bleeds/number of days during the efficacy period) x 365.25. A bleed is considered a &quot;treated bleed&quot; if it is directly followed (i.e., no intervening bleed) by a hemophilia medication reported to be a &quot;treatment for bleed&quot;, irrespective of time between treatment and the preceding bleed. A bleed and the first treatment thereafter and before a new bleed starts, are considered to be pairs, with the following exception: if multiple bleeds occur on the same calendar day, the subsequent treatment is considered to apply for each of these multiple bleeds. The 72-hour rule was implemented: two bleeds of the same type and at the same anatomical location are counted as one bleed if the second bleed occurs within 72 hours from the last treatment for the first bleed. Bleeds due to surgery/procedure are excluded.</div><br/>
            	<li style="margin-top:0.7ex;">Cohort A: Median Calculated Annualized Bleed Rate (ABR) for All Bleeds in Treated Participants &lt;12 Years of Age [&nbsp;Time&nbsp;Frame:&nbsp;From Baseline to 52 weeks; At the primary completion date, the median (min-max) duration of the efficacy period in Cohort A was 57.57 (17.9-92.6) weeks.&nbsp;]<div class="tr-indent2" style="margin-top:1ex;">The number of all bleeds over the efficacy period is presented here as a calculated ABR that was annualized for each participant using the following formula: ABR = (number of bleeds/number of days during the efficacy period) x 365.25. In this outcome measure, all bleeds are included, irrespective of treatment with coagulation factors, with the following exception: bleeds due to surgery/procedure are excluded. As &quot;all bleeds&quot; comprises both treated and non-treated bleeds, the 72-hour rule was implemented separately for treated and non-treated bleeds. For treated bleeds, the 72-hour rule was implemented exactly as defined for the &quot;treated bleeds&quot; outcome measure. For non-treated bleeds, the 72-hour rule was implemented by calculating a treatment-free period of 72 hours from the bleed itself.</div><br/>
            	<li style="margin-top:0.7ex;">Cohort A: Median Calculated Annualized Bleed Rate (ABR) for Treated Spontaneous Bleeds in Treated Participants &lt;12 Years of Age [&nbsp;Time&nbsp;Frame:&nbsp;From Baseline to 52 weeks; At the primary completion date, the median (min-max) duration of the efficacy period in Cohort A was 57.57 (17.9-92.6) weeks.&nbsp;]<div class="tr-indent2" style="margin-top:1ex;">The number of treated spontaneous bleeds over the efficacy period is presented here as a calculated ABR that was annualized for each participant using the following formula: ABR = (number of bleeds/number of days during the efficacy period) x 365.25. A bleed is classified as &quot;spontaneous&quot; if there is no other known contributing factor such as trauma or procedure/surgery. A &quot;treated spontaneous bleed&quot; is a spontaneous bleed that also fulfills the conditions of a treated bleed (see ABR for Treated Bleeds for the definition). Treated bleeds that fulfilled the 72-hour rule were included in the analysis of spontaneous bleeds. Bleeds due to surgery/procedure are excluded.</div><br/>
            	<li style="margin-top:0.7ex;">Cohort A: Median Calculated Annualized Bleed Rate (ABR) for Treated Joint Bleeds in Treated Participants &lt;12 Years of Age [&nbsp;Time&nbsp;Frame:&nbsp;From Baseline to 52 weeks; At the primary completion date, the median (min-max) duration of the efficacy period in Cohort A was 57.57 (17.9-92.6) weeks.&nbsp;]<div class="tr-indent2" style="margin-top:1ex;">The number of treated joint bleeds over the efficacy period is presented here as a calculated ABR that was annualized for each participant using the following formula: ABR = (number of bleeds/number of days during the efficacy period) x 365.25. A &quot;joint bleed&quot; is defined as a bleed with type reported as &quot;joint&quot; and with at least one of the following symptoms: increasing swelling or warmth of the skin over the joint and/or increasing pain, decreased range of motion, or difficulty using the joint compared with baseline. A &quot;treated joint bleed&quot; is a joint bleed that also fulfills the conditions of a treated bleed (see ABR for Treated Bleeds for the definition). Only treated bleeds that fulfilled the 72-hour rule were included in the analysis of treated joint bleeds, excluding bleeds due to surgery/procedure.</div><br/>
            	<li style="margin-top:0.7ex;">Cohort A: Median Calculated Annualized Bleed Rate (ABR) for Treated Target Joint Bleeds in Treated Participants &lt;12 Years of Age [&nbsp;Time&nbsp;Frame:&nbsp;From Baseline to 52 weeks; At the primary completion date, the median (min-max) duration of the efficacy period in Cohort A was 57.57 (17.9-92.6) weeks.&nbsp;]<div class="tr-indent2" style="margin-top:1ex;">The number of treated target joint bleeds over the efficacy period is presented here as a calculated ABR that was annualized for each participant using the following formula: ABR = (number of bleeds/number of days during the efficacy period) x 365.25. A &quot;target joint bleed&quot; is defined as a joint bleed in a target joint, which is a joint location where at least 3 bleeds have occurred over the last 24 weeks prior to study entry. A &quot;treated target joint bleed&quot; is a target joint bleed that also fulfills the conditions of a treated bleed (see ABR for Treated Bleeds for the definition). Bleeds due to surgery/procedure are excluded.</div><br/>
            	<li style="margin-top:0.7ex;">Cohort A: Percentage of Participants by Categorized Number of Treated Bleeds Over the Efficacy Period in Treated Participants &lt;12 Years of Age [&nbsp;Time&nbsp;Frame:&nbsp;From Baseline to 52 weeks; At the primary completion date, the median (min-max) duration of the efficacy period in Cohort A was 57.57 (17.9-92.6) weeks.&nbsp;]<div class="tr-indent2" style="margin-top:1ex;">The percentage of participants by categorized number of treated bleeds over the efficacy period is presented here. A bleed is considered a &quot;treated bleed&quot; if it is directly followed (i.e., no intervening bleed) by a hemophilia medication reported to be a &quot;treatment for bleed&quot;, irrespective of time between treatment and the preceding bleed. A bleed and the first treatment thereafter and before a new bleed starts, are considered to be pairs, with the following exception: if multiple bleeds occur on the same calendar day, the subsequent treatment is considered to apply for each of these multiple bleeds. The 72-hour rule was implemented: two bleeds of the same type and at the same anatomical location are counted as one bleed if the second bleed occurs within 72 hours from the last treatment for the first bleed. Bleeds due to surgery/procedure are excluded.</div><br/>
            	<li style="margin-top:0.7ex;">Cohort A: Percentage of Participants by Categorized Number of All Bleeds Over the Efficacy Period in Treated Participants &lt;12 Years of Age [&nbsp;Time&nbsp;Frame:&nbsp;From Baseline to 52 weeks; At the primary completion date, the median (min-max) duration of the efficacy period in Cohort A was 57.57 (17.9-92.6) weeks.&nbsp;]<div class="tr-indent2" style="margin-top:1ex;">The percentage of participants by categorized number of all bleeds over the efficacy period is presented here. In this outcome measure, all bleeds are included, irrespective of treatment with coagulation factors, with the following exception: bleeds due to surgery/procedure are excluded. As &quot;all bleeds&quot; comprises both treated and non-treated bleeds, the 72-hour rule was implemented separately for treated and non-treated bleeds. For treated bleeds, the 72-hour rule was implemented exactly as defined for the &quot;treated bleeds&quot; outcome measure. For non-treated bleeds, the 72-hour rule was implemented by calculating a treatment-free period of 72 hours from the bleed itself.</div><br/>
            	<li style="margin-top:0.7ex;">Cohort A: Percentage of Participants by Categorized Number of Treated Spontaneous Bleeds Over the Efficacy Period in Treated Participants &lt;12 Years of Age [&nbsp;Time&nbsp;Frame:&nbsp;From Baseline to 52 weeks; At the primary completion date, the median (min-max) duration of the efficacy period in Cohort A was 57.57 (17.9-92.6) weeks.&nbsp;]<div class="tr-indent2" style="margin-top:1ex;">The percentage of participants by categorized number of treated spontaneous bleeds over the efficacy period is presented here. A bleed is classified as &quot;spontaneous&quot; if there is no other known contributing factor such as trauma or procedure/surgery. A &quot;treated spontaneous bleed&quot; is a spontaneous bleed that also fulfills the conditions of a treated bleed (see ABR for Treated Bleeds for the definition). Treated bleeds that fulfilled the 72-hour rule were included in the analysis of spontaneous bleeds. Bleeds due to surgery/procedure are excluded.</div><br/>
            	<li style="margin-top:0.7ex;">Cohort A: Percentage of Participants by Categorized Number of Treated Joint Bleeds Over the Efficacy Period in Treated Participants &lt;12 Years of Age [&nbsp;Time&nbsp;Frame:&nbsp;From Baseline to 52 weeks; At the primary completion date, the median (min-max) duration of the efficacy period in Cohort A was 57.57 (17.9-92.6) weeks.&nbsp;]<div class="tr-indent2" style="margin-top:1ex;">The percentage of participants by categorized number of treated joint bleeds over the efficacy period is presented here. A &quot;joint bleed&quot; is defined as a bleed with type reported as &quot;joint&quot; and with at least one of the following symptoms: increasing swelling or warmth of the skin over the joint and/or increasing pain, decreased range of motion, or difficulty using the joint compared with baseline. A &quot;treated joint bleed&quot; is a joint bleed that also fulfills the conditions of a treated bleed (see ABR for Treated Bleeds for the definition). Only treated bleeds that fulfilled the 72-hour rule were included in the analysis of treated joint bleeds, excluding bleeds due to surgery/procedure.</div><br/>
            	<li style="margin-top:0.7ex;">Cohort A: Percentage of Participants by Categorized Number of Treated Target Joint Bleeds Over the Efficacy Period in Treated Participants &lt;12 Years of Age [&nbsp;Time&nbsp;Frame:&nbsp;From Baseline to 52 weeks; At the primary completion date, the median (min-max) duration of the efficacy period in Cohort A was 57.57 (17.9-92.6) weeks.&nbsp;]<div class="tr-indent2" style="margin-top:1ex;">The percentage of participants by categorized number of treated target joint bleeds over the efficacy period is presented here. A &quot;target joint bleed&quot; is defined as a joint bleed in a target joint, which is a joint location where at least 3 bleeds have occurred over the last 24 weeks prior to study entry. A &quot;treated target joint bleed&quot; is a target joint bleed that also fulfills the conditions of a treated bleed (see ABR for Treated Bleeds for the definition). Bleeds due to surgery/procedure are excluded.</div><br/>
            </ol>
    </div>
    <br/>
    
        <!-- secondary outcomes -->
    <div class="ct-body3"  style="margin-right:1em;">
<span style="display:inline;" class="term" data-term="Secondary Outcome Measure" title="Show definition">Secondary Outcome Measures <i class="fa fa-info-circle term" aria-hidden="true" data-term="Secondary Outcome Measure" style="border-bottom-style:none;"></i></span> :
      <ol style="margin-top:1ex; margin-bottom:1ex;">
            <li style="margin-top:0.7ex;">Cohorts B and C: Model-Based Annualized Bleed Rate (ABR) for Treated Bleeds in Treated Participants &lt;12 Years of Age [&nbsp;Time&nbsp;Frame:&nbsp;From Baseline to 24 weeks; At the primary completion date, the median (min-max) duration of the efficacy periods in Cohorts B and C were 21.29 (18.6-24.1) weeks and 19.86 (8.9-24.1) weeks, respectively.&nbsp;]<div class="tr-indent2" style="margin-top:1ex;">The number of treated bleeds over the efficacy period is presented as a model-based ABR that was analyzed using a negative binomial regression model with efficacy period as an offset to account for the difference in follow-up times. A bleed is considered a &quot;treated bleed&quot; if it is directly followed (i.e., no intervening bleed) by a hemophilia medication reported to be a &quot;treatment for bleed&quot;, irrespective of time between treatment and the preceding bleed. A bleed and the first treatment thereafter and before a new bleed starts, are considered to be pairs, with the following exception: if multiple bleeds occur on the same calendar day, the subsequent treatment is considered to apply for each of these multiple bleeds. The 72-hour rule was implemented: two bleeds of the same type and at the same anatomical location are counted as one bleed if the second bleed occurs within 72 hours from the last treatment for the first bleed. Bleeds due to surgery/procedure are excluded.</div><br/>
            <li style="margin-top:0.7ex;">Cohorts B and C: Model-Based Annualized Bleed Rate (ABR) for All Bleeds in Treated Participants &lt;12 Years of Age [&nbsp;Time&nbsp;Frame:&nbsp;From Baseline to 24 weeks; At the primary completion date, the median (min-max) duration of the efficacy periods in Cohorts B and C were 21.29 (18.6-24.1) weeks and 19.86 (8.9-24.1) weeks, respectively.&nbsp;]<div class="tr-indent2" style="margin-top:1ex;">The number of all bleeds over the efficacy period is presented as a model-based ABR that was analyzed using a negative binomial regression model with efficacy period as an offset to account for the difference in follow-up times (i.e., the time that each participant stays in the study). In this outcome measure, all bleeds are included, irrespective of treatment with coagulation factors, with the following exception: bleeds due to surgery/procedure are excluded. As &quot;all bleeds&quot; comprises both treated and non-treated bleeds, the 72-hour rule was implemented separately for treated and non-treated bleeds. For treated bleeds, the 72-hour rule was implemented exactly as defined for the &quot;treated bleeds&quot; outcome measure. For non-treated bleeds, the 72-hour rule was implemented by calculating a treatment-free period of 72 hours from the bleed itself.</div><br/>
            <li style="margin-top:0.7ex;">Cohorts B and C: Model-Based Annualized Bleed Rate (ABR) for Treated Spontaneous Bleeds in Treated Participants &lt;12 Years of Age [&nbsp;Time&nbsp;Frame:&nbsp;From Baseline to 24 weeks; At the primary completion date, the median (min-max) duration of the efficacy periods in Cohorts B and C were 21.29 (18.6-24.1) weeks and 19.86 (8.9-24.1) weeks, respectively.&nbsp;]<div class="tr-indent2" style="margin-top:1ex;">The number of treated spontaneous bleeds over the efficacy period is presented as a model-based ABR that was analyzed using a negative binomial regression model with efficacy period as an offset to account for the difference in follow-up times (i.e., the time that each participant stays in the study). A bleed is classified as &quot;spontaneous&quot; if there is no other known contributing factor such as trauma or procedure/surgery. A &quot;treated spontaneous bleed&quot; is a spontaneous bleed that also fulfills the conditions of a treated bleed (see ABR for Treated Bleeds for the definition). Treated bleeds that fulfilled the 72-hour rule were included in the analysis of spontaneous bleeds. Bleeds due to surgery/procedure are excluded.</div><br/>
            <li style="margin-top:0.7ex;">Cohorts B and C: Model-Based Annualized Bleed Rate (ABR) for Treated Joint Bleeds in Treated Participants &lt;12 Years of Age [&nbsp;Time&nbsp;Frame:&nbsp;From Baseline to 24 weeks; At the primary completion date, the median (min-max) duration of the efficacy periods in Cohorts B and C were 21.29 (18.6-24.1) weeks and 19.86 (8.9-24.1) weeks, respectively.&nbsp;]<div class="tr-indent2" style="margin-top:1ex;">The number of treated joint bleeds over the efficacy period is presented as a model-based ABR that was analyzed using a negative binomial regression model with efficacy period as an offset to account for the difference in follow-up times (i.e., the time that each participant stays in the study). A &quot;joint bleed&quot; is defined as a bleed with type reported as &quot;joint&quot; and with at least one of the following symptoms: increasing swelling or warmth of the skin over the joint and/or increasing pain, decreased range of motion, or difficulty using the joint compared with baseline. A &quot;treated joint bleed&quot; is a joint bleed that also fulfills the conditions of a treated bleed (see ABR for Treated Bleeds for the definition). Only treated bleeds that fulfilled the 72-hour rule were included in the analysis of treated joint bleeds, excluding bleeds due to surgery/procedure.</div><br/>
            <li style="margin-top:0.7ex;">Cohorts B and C: Model-Based Annualized Bleed Rate (ABR) for Treated Target Joint Bleeds in Treated Participants &lt;12 Years of Age [&nbsp;Time&nbsp;Frame:&nbsp;From Baseline to 24 weeks; At the primary completion date, the median (min-max) duration of the efficacy periods in Cohorts B and C were 21.29 (18.6-24.1) weeks and 19.86 (8.9-24.1) weeks, respectively.&nbsp;]<div class="tr-indent2" style="margin-top:1ex;">The number of treated target joint bleeds over the efficacy period is presented as a model-based ABR that was analyzed using a negative binomial regression model with efficacy period as an offset to account for the difference in follow-up times (i.e., the time that each participant stays in the study). A &quot;target joint bleed&quot; is defined as a joint bleed in a target joint, which is a joint location where at least 3 bleeds have occurred over the last 24 weeks prior to study entry. A &quot;treated target joint bleed&quot; is a target joint bleed that also fulfills the conditions of a treated bleed (see ABR for Treated Bleeds for the definition). Bleeds due to surgery/procedure are excluded.</div><br/>
            <li style="margin-top:0.7ex;">Cohorts B and C: Mean Calculated Annualized Bleed Rate (ABR) for Treated Bleeds in Treated Participants &lt;12 Years of Age [&nbsp;Time&nbsp;Frame:&nbsp;From Baseline to 24 weeks; At the primary completion date, the median (min-max) duration of the efficacy periods in Cohorts B and C were 21.29 (18.6-24.1) weeks and 19.86 (8.9-24.1) weeks, respectively.&nbsp;]<div class="tr-indent2" style="margin-top:1ex;">The number of treated bleeds over the efficacy period is presented here as a calculated ABR that was annualized for each participant using the following formula: ABR = (number of bleeds/number of days during the efficacy period) x 365.25. A bleed is considered a &quot;treated bleed&quot; if it is directly followed (i.e., no intervening bleed) by a hemophilia medication reported to be a &quot;treatment for bleed&quot;, irrespective of time between treatment and the preceding bleed. A bleed and the first treatment thereafter and before a new bleed starts, are considered to be pairs, with the following exception: if multiple bleeds occur on the same calendar day, the subsequent treatment is considered to apply for each of these multiple bleeds. The 72-hour rule was implemented: two bleeds of the same type and at the same anatomical location are counted as one bleed if the second bleed occurs within 72 hours from the last treatment for the first bleed. Bleeds due to surgery/procedure are excluded.</div><br/>
            <li style="margin-top:0.7ex;">Cohorts B and C: Mean Calculated Annualized Bleed Rate (ABR) for All Bleeds in Treated Participants &lt;12 Years of Age [&nbsp;Time&nbsp;Frame:&nbsp;From Baseline to 24 weeks; At the primary completion date, the median (min-max) duration of the efficacy periods in Cohorts B and C were 21.29 (18.6-24.1) weeks and 19.86 (8.9-24.1) weeks, respectively.&nbsp;]<div class="tr-indent2" style="margin-top:1ex;">The number of all bleeds over the efficacy period is presented here as a calculated ABR that was annualized for each participant using the following formula: ABR = (number of bleeds/number of days during the efficacy period) x 365.25. In this outcome measure, all bleeds are included, irrespective of treatment with coagulation factors, with the following exception: bleeds due to surgery/procedure are excluded. As &quot;all bleeds&quot; comprises both treated and non-treated bleeds, the 72-hour rule was implemented separately for treated and non-treated bleeds. For treated bleeds, the 72-hour rule was implemented exactly as defined for the &quot;treated bleeds&quot; outcome measure. For non-treated bleeds, the 72-hour rule was implemented by calculating a treatment-free period of 72 hours from the bleed itself.</div><br/>
            <li style="margin-top:0.7ex;">Cohorts B and C: Mean Calculated Annualized Bleed Rate (ABR) for Treated Spontaneous Bleeds in Treated Participants &lt;12 Years of Age [&nbsp;Time&nbsp;Frame:&nbsp;From Baseline to 24 weeks; At the primary completion date, the median (min-max) duration of the efficacy periods in Cohorts B and C were 21.29 (18.6-24.1) weeks and 19.86 (8.9-24.1) weeks, respectively.&nbsp;]<div class="tr-indent2" style="margin-top:1ex;">The number of treated spontaneous bleeds over the efficacy period is presented here as a calculated ABR that was annualized for each participant using the following formula: ABR = (number of bleeds/number of days during the efficacy period) x 365.25. A bleed is classified as &quot;spontaneous&quot; if there is no other known contributing factor such as trauma or procedure/surgery. A &quot;treated spontaneous bleed&quot; is a spontaneous bleed that also fulfills the conditions of a treated bleed (see ABR for Treated Bleeds for the definition). Treated bleeds that fulfilled the 72-hour rule were included in the analysis of spontaneous bleeds. Bleeds due to surgery/procedure are excluded.</div><br/>
            <li style="margin-top:0.7ex;">Cohorts B and C: Mean Calculated Annualized Bleed Rate (ABR) for Treated Joint Bleeds in Treated Participants &lt;12 Years of Age [&nbsp;Time&nbsp;Frame:&nbsp;From Baseline to 24 weeks; At the primary completion date, the median (min-max) duration of the efficacy periods in Cohorts B and C were 21.29 (18.6-24.1) weeks and 19.86 (8.9-24.1) weeks, respectively.&nbsp;]<div class="tr-indent2" style="margin-top:1ex;">The number of treated joint bleeds over the efficacy period is presented here as a calculated ABR that was annualized for each participant using the following formula: ABR = (number of bleeds/number of days during the efficacy period) x 365.25. A &quot;joint bleed&quot; is defined as a bleed with type reported as &quot;joint&quot; and with at least one of the following symptoms: increasing swelling or warmth of the skin over the joint and/or increasing pain, decreased range of motion, or difficulty using the joint compared with baseline. A &quot;treated joint bleed&quot; is a joint bleed that also fulfills the conditions of a treated bleed (see ABR for Treated Bleeds for the definition). Only treated bleeds that fulfilled the 72-hour rule were included in the analysis of treated joint bleeds, excluding bleeds due to surgery/procedure.</div><br/>
            <li style="margin-top:0.7ex;">Cohorts B and C: Mean Calculated Annualized Bleed Rate (ABR) for Treated Target Joint Bleeds in Treated Participants &lt;12 Years of Age [&nbsp;Time&nbsp;Frame:&nbsp;From Baseline to 24 weeks; At the primary completion date, the median (min-max) duration of the efficacy periods in Cohorts B and C were 21.29 (18.6-24.1) weeks and 19.86 (8.9-24.1) weeks, respectively.&nbsp;]<div class="tr-indent2" style="margin-top:1ex;">The number of treated target joint bleeds over the efficacy period is presented here as a calculated ABR that was annualized for each participant using the following formula: ABR = (number of bleeds/number of days during the efficacy period) x 365.25. A &quot;target joint bleed&quot; is defined as a joint bleed in a target joint, which is a joint location where at least 3 bleeds have occurred over the last 24 weeks prior to study entry. A &quot;treated target joint bleed&quot; is a target joint bleed that also fulfills the conditions of a treated bleed (see ABR for Treated Bleeds for the definition). Bleeds due to surgery/procedure are excluded.</div><br/>
            <li style="margin-top:0.7ex;">Cohorts B and C: Median Calculated Annualized Bleed Rate (ABR) for Treated Bleeds in Treated Participants &lt;12 Years of Age [&nbsp;Time&nbsp;Frame:&nbsp;From Baseline to 24 weeks; At the primary completion date, the median (min-max) duration of the efficacy periods in Cohorts B and C were 21.29 (18.6-24.1) weeks and 19.86 (8.9-24.1) weeks, respectively.&nbsp;]<div class="tr-indent2" style="margin-top:1ex;">The number of treated bleeds over the efficacy period is presented here as a calculated ABR that was annualized for each participant using the following formula: ABR = (number of bleeds/number of days during the efficacy period) x 365.25. A bleed is considered a &quot;treated bleed&quot; if it is directly followed (i.e., no intervening bleed) by a hemophilia medication reported to be a &quot;treatment for bleed&quot;, irrespective of time between treatment and the preceding bleed. A bleed and the first treatment thereafter and before a new bleed starts, are considered to be pairs, with the following exception: if multiple bleeds occur on the same calendar day, the subsequent treatment is considered to apply for each of these multiple bleeds. The 72-hour rule was implemented: two bleeds of the same type and at the same anatomical location are counted as one bleed if the second bleed occurs within 72 hours from the last treatment for the first bleed. Bleeds due to surgery/procedure are excluded.</div><br/>
            <li style="margin-top:0.7ex;">Cohorts B and C: Median Calculated Annualized Bleed Rate (ABR) for All Bleeds in Treated Participants &lt;12 Years of Age [&nbsp;Time&nbsp;Frame:&nbsp;From Baseline to 24 weeks; At the primary completion date, the median (min-max) duration of the efficacy periods in Cohorts B and C were 21.29 (18.6-24.1) weeks and 19.86 (8.9-24.1) weeks, respectively.&nbsp;]<div class="tr-indent2" style="margin-top:1ex;">The number of all bleeds over the efficacy period is presented here as a calculated ABR that was annualized for each participant using the following formula: ABR = (number of bleeds/number of days during the efficacy period) x 365.25. In this outcome measure, all bleeds are included, irrespective of treatment with coagulation factors, with the following exception: bleeds due to surgery/procedure are excluded. As &quot;all bleeds&quot; comprises both treated and non-treated bleeds, the 72-hour rule was implemented separately for treated and non-treated bleeds. For treated bleeds, the 72-hour rule was implemented exactly as defined for the &quot;treated bleeds&quot; outcome measure. For non-treated bleeds, the 72-hour rule was implemented by calculating a treatment-free period of 72 hours from the bleed itself.</div><br/>
            <li style="margin-top:0.7ex;">Cohorts B and C: Median Calculated Annualized Bleed Rate (ABR) for Treated Spontaneous Bleeds in Treated Participants &lt;12 Years of Age [&nbsp;Time&nbsp;Frame:&nbsp;From Baseline to 24 weeks; At the primary completion date, the median (min-max) duration of the efficacy periods in Cohorts B and C were 21.29 (18.6-24.1) weeks and 19.86 (8.9-24.1) weeks, respectively.&nbsp;]<div class="tr-indent2" style="margin-top:1ex;">The number of treated spontaneous bleeds over the efficacy period is presented here as a calculated ABR that was annualized for each participant using the following formula: ABR = (number of bleeds/number of days during the efficacy period) x 365.25. A bleed is classified as &quot;spontaneous&quot; if there is no other known contributing factor such as trauma or procedure/surgery. A &quot;treated spontaneous bleed&quot; is a spontaneous bleed that also fulfills the conditions of a treated bleed (see ABR for Treated Bleeds for the definition). Treated bleeds that fulfilled the 72-hour rule were included in the analysis of spontaneous bleeds. Bleeds due to surgery/procedure are excluded.</div><br/>
            <li style="margin-top:0.7ex;">Cohorts B and C: Median Calculated Annualized Bleed Rate (ABR) for Treated Joint Bleeds in Treated Participants &lt;12 Years of Age [&nbsp;Time&nbsp;Frame:&nbsp;From Baseline to 24 weeks; At the primary completion date, the median (min-max) duration of the efficacy periods in Cohorts B and C were 21.29 (18.6-24.1) weeks and 19.86 (8.9-24.1) weeks, respectively.&nbsp;]<div class="tr-indent2" style="margin-top:1ex;">The number of treated joint bleeds over the efficacy period is presented here as a calculated ABR that was annualized for each participant using the following formula: ABR = (number of bleeds/number of days during the efficacy period) x 365.25. A &quot;joint bleed&quot; is defined as a bleed with type reported as &quot;joint&quot; and with at least one of the following symptoms: increasing swelling or warmth of the skin over the joint and/or increasing pain, decreased range of motion, or difficulty using the joint compared with baseline. A &quot;treated joint bleed&quot; is a joint bleed that also fulfills the conditions of a treated bleed (see ABR for Treated Bleeds for the definition). Only treated bleeds that fulfilled the 72-hour rule were included in the analysis of treated joint bleeds, excluding bleeds due to surgery/procedure.</div><br/>
            <li style="margin-top:0.7ex;">Cohorts B and C: Median Calculated Annualized Bleed Rate (ABR) for Treated Target Joint Bleeds in Treated Participants &lt;12 Years of Age [&nbsp;Time&nbsp;Frame:&nbsp;From Baseline to 24 weeks; At the primary completion date, the median (min-max) duration of the efficacy periods in Cohorts B and C were 21.29 (18.6-24.1) weeks and 19.86 (8.9-24.1) weeks, respectively.&nbsp;]<div class="tr-indent2" style="margin-top:1ex;">The number of treated target joint bleeds over the efficacy period is presented here as a calculated ABR that was annualized for each participant using the following formula: ABR = (number of bleeds/number of days during the efficacy period) x 365.25. A &quot;target joint bleed&quot; is defined as a joint bleed in a target joint, which is a joint location where at least 3 bleeds have occurred over the last 24 weeks prior to study entry. A &quot;treated target joint bleed&quot; is a target joint bleed that also fulfills the conditions of a treated bleed (see ABR for Treated Bleeds for the definition). Bleeds due to surgery/procedure are excluded.</div><br/>
            <li style="margin-top:0.7ex;">Cohorts B and C: Percentage of Participants by Categorized Number of Treated Bleeds Over the Efficacy Period in Treated Participants &lt;12 Years of Age [&nbsp;Time&nbsp;Frame:&nbsp;From Baseline to 24 weeks; At the primary completion date, the median (min-max) duration of the efficacy periods in Cohorts B and C were 21.29 (18.6-24.1) weeks and 19.86 (8.9-24.1) weeks, respectively.&nbsp;]<div class="tr-indent2" style="margin-top:1ex;">The percentage of participants by categorized number of treated bleeds over the efficacy period is presented here. A bleed is considered a &quot;treated bleed&quot; if it is directly followed (i.e., no intervening bleed) by a hemophilia medication reported to be a &quot;treatment for bleed&quot;, irrespective of time between treatment and the preceding bleed. A bleed and the first treatment thereafter and before a new bleed starts, are considered to be pairs, with the following exception: if multiple bleeds occur on the same calendar day, the subsequent treatment is considered to apply for each of these multiple bleeds. The 72-hour rule was implemented: two bleeds of the same type and at the same anatomical location are counted as one bleed if the second bleed occurs within 72 hours from the last treatment for the first bleed. Bleeds due to surgery/procedure are excluded.</div><br/>
            <li style="margin-top:0.7ex;">Cohorts B and C: Percentage of Participants by Categorized Number of All Bleeds Over the Efficacy Period in Treated Participants &lt;12 Years of Age [&nbsp;Time&nbsp;Frame:&nbsp;From Baseline to 24 weeks; At the primary completion date, the median (min-max) duration of the efficacy periods in Cohorts B and C were 21.29 (18.6-24.1) weeks and 19.86 (8.9-24.1) weeks, respectively.&nbsp;]<div class="tr-indent2" style="margin-top:1ex;">The percentage of participants by categorized number of all bleeds over the efficacy period is presented here. In this outcome measure, all bleeds are included, irrespective of treatment with coagulation factors, with the following exception: bleeds due to surgery/procedure are excluded. As &quot;all bleeds&quot; comprises both treated and non-treated bleeds, the 72-hour rule was implemented separately for treated and non-treated bleeds. For treated bleeds, the 72-hour rule was implemented exactly as defined for the &quot;treated bleeds&quot; outcome measure. For non-treated bleeds, the 72-hour rule was implemented by calculating a treatment-free period of 72 hours from the bleed itself.</div><br/>
            <li style="margin-top:0.7ex;">Cohorts B and C: Percentage of Participants by Categorized Number of Treated Spontaneous Bleeds Over the Efficacy Period in Treated Participants &lt;12 Years of Age [&nbsp;Time&nbsp;Frame:&nbsp;From Baseline to 24 weeks; At the primary completion date, the median (min-max) duration of the efficacy periods in Cohorts B and C were 21.29 (18.6-24.1) weeks and 19.86 (8.9-24.1) weeks, respectively.&nbsp;]<div class="tr-indent2" style="margin-top:1ex;">The percentage of participants by categorized number of treated spontaneous bleeds over the efficacy period is presented here. A bleed is classified as &quot;spontaneous&quot; if there is no other known contributing factor such as trauma or procedure/surgery. A &quot;treated spontaneous bleed&quot; is a spontaneous bleed that also fulfills the conditions of a treated bleed (see ABR for Treated Bleeds for the definition). Treated bleeds that fulfilled the 72-hour rule were included in the analysis of spontaneous bleeds. Bleeds due to surgery/procedure are excluded.</div><br/>
            <li style="margin-top:0.7ex;">Cohorts B and C: Percentage of Participants by Categorized Number of Treated Joint Bleeds Over the Efficacy Period in Treated Participants &lt;12 Years of Age [&nbsp;Time&nbsp;Frame:&nbsp;From Baseline to 24 weeks; At the primary completion date, the median (min-max) duration of the efficacy periods in Cohorts B and C were 21.29 (18.6-24.1) weeks and 19.86 (8.9-24.1) weeks, respectively.&nbsp;]<div class="tr-indent2" style="margin-top:1ex;">The percentage of participants by categorized number of treated joint bleeds over the efficacy period is presented here. A &quot;joint bleed&quot; is defined as a bleed with type reported as &quot;joint&quot; and with at least one of the following symptoms: increasing swelling or warmth of the skin over the joint and/or increasing pain, decreased range of motion, or difficulty using the joint compared with baseline. A &quot;treated joint bleed&quot; is a joint bleed that also fulfills the conditions of a treated bleed (see ABR for Treated Bleeds for the definition). Only treated bleeds that fulfilled the 72-hour rule were included in the analysis of treated joint bleeds, excluding bleeds due to surgery/procedure.</div><br/>
            <li style="margin-top:0.7ex;">Cohorts B and C: Percentage of Participants by Categorized Number of Treated Target Joint Bleeds Over the Efficacy Period in Treated Participants &lt;12 Years of Age [&nbsp;Time&nbsp;Frame:&nbsp;From Baseline to 24 weeks; At the primary completion date, the median (min-max) duration of the efficacy periods in Cohorts B and C were 21.29 (18.6-24.1) weeks and 19.86 (8.9-24.1) weeks, respectively.&nbsp;]<div class="tr-indent2" style="margin-top:1ex;">The percentage of participants by categorized number of treated target joint bleeds over the efficacy period is presented here. A &quot;target joint bleed&quot; is defined as a joint bleed in a target joint, which is a joint location where at least 3 bleeds have occurred over the last 24 weeks prior to study entry. A &quot;treated target joint bleed&quot; is a target joint bleed that also fulfills the conditions of a treated bleed (see ABR for Treated Bleeds for the definition). Bleeds due to surgery/procedure are excluded.</div><br/>
            <li style="margin-top:0.7ex;">Cohort A: Intra-Participant Comparison of the Model-Based ABR for Treated Bleeds on Study Versus Pre-Study in Treated Participants &lt;12 Years of Age From the Non-Interventional Study (NIS) Population [&nbsp;Time&nbsp;Frame:&nbsp;Up to 24 weeks in NIS BH29768 (NCT02476942) prior to study entry and from Baseline to 52 weeks on this study; At primary completion date, the median (min-max) duration of the efficacy period in the NIS population was 88.57 (55.9-92.6) weeks.&nbsp;]<div class="tr-indent2" style="margin-top:1ex;">This is an intra-participant comparison of the model-based annualized bleeding rate (ABR) for treated bleeds (i.e., number of treated bleeds over efficacy period using negative binomial regression model) on study versus pre-study in the NIS population who had previously participated in study BH29768 (NCT02476942). A &quot;treated bleed&quot; is a bleed directly followed by a hemophilia medication reported to be a &quot;treatment for bleed&quot;, irrespective of time between treatment and the preceding bleed. A bleed and first treatment thereafter are considered to be pairs, with the following exception: if multiple bleeds occur on the same calendar day, the subsequent treatment is considered to apply for each of these multiple bleeds. The 72-hour rule was implemented: two bleeds of the same type and at the same anatomical location are counted as one bleed if the second bleed occurs within 72 hours from the last treatment for the first bleed. Bleeds due to surgery/procedure are excluded.</div><br/>
            <li style="margin-top:0.7ex;">Cohort A: Intra-Participant Comparison of the Model-Based ABR for All Bleeds on Study Versus Pre-Study in Treated Participants &lt;12 Years of Age From the NIS Population [&nbsp;Time&nbsp;Frame:&nbsp;Up to 24 weeks in NIS BH29768 (NCT02476942) prior to study entry and from Baseline to 52 weeks on this study; At primary completion date, the median (min-max) duration of the efficacy period in the NIS population was 88.57 (55.9-92.6) weeks.&nbsp;]<div class="tr-indent2" style="margin-top:1ex;">This is an intra-participant comparison of the model-based annualized bleeding rate (ABR) for all bleeds (i.e., number of all bleeds over efficacy period using negative binomial regression model) on study versus pre-study in the NIS population who had previously participated in study BH29768 (NCT02476942). In this outcome measure, all bleeds are included, irrespective of treatment with coagulation factors, with the following exception: bleeds due to surgery/procedure are excluded. As &quot;all bleeds&quot; comprises both treated and non-treated bleeds, the 72-hour rule was implemented separately for treated and non-treated bleeds. For treated bleeds, the 72-hour rule was implemented exactly as defined for the &quot;treated bleeds&quot; outcome measure. For non-treated bleeds, the 72-hour rule was implemented by calculating a treatment-free period of 72 hours from the bleed itself.</div><br/>
            <li style="margin-top:0.7ex;">Cohort A: Intra-Participant Comparison of the Median Calculated ABR for Treated Bleeds on Study Versus Pre-Study in Treated Participants &lt;12 Years of Age From the NIS Population [&nbsp;Time&nbsp;Frame:&nbsp;Up to 24 weeks in NIS BH29768 (NCT02476942) prior to study entry and from Baseline to 52 weeks on this study; At primary completion date, the median (min-max) duration of the efficacy period in the NIS population was 88.57 (55.9-92.6) weeks.&nbsp;]<div class="tr-indent2" style="margin-top:1ex;">This is an intra-participant comparison of the calculated ABR for treated bleeds (annualized per participant using the following formula: ABR = [number of bleeds/number of days during the efficacy period] x 365.25) on study versus pre-study in the NIS population who had previously participated in study BH29768 (NCT02476942). A &quot;treated bleed&quot; is a bleed directly followed by a hemophilia medication reported to be a &quot;treatment for bleed&quot;, irrespective of time between treatment and the preceding bleed. A bleed and first treatment thereafter are considered to be pairs, with the following exception: if multiple bleeds occur on the same calendar day, the subsequent treatment is considered to apply for each of these multiple bleeds. The 72-hour rule was implemented: two bleeds of the same type and at the same anatomical location are counted as one bleed if the second bleed occurs within 72 hours from the last treatment for the first bleed. Bleeds due to surgery/procedure are excluded.</div><br/>
            <li style="margin-top:0.7ex;">Cohort A: Intra-Participant Comparison of the Median Calculated ABR for All Bleeds on Study Versus Pre-Study in Treated Participants &lt;12 Years of Age From the NIS Population [&nbsp;Time&nbsp;Frame:&nbsp;Up to 24 weeks in NIS BH29768 (NCT02476942) prior to study entry and from Baseline to 52 weeks on this study; At primary completion date, the median (min-max) duration of the efficacy period in the NIS population was 88.57 (55.9-92.6) weeks.&nbsp;]<div class="tr-indent2" style="margin-top:1ex;">This is an intra-participant comparison of the calculated annualized bleeding rate (ABR) for all bleeds (annualized for each participant using the following formula: ABR = [number of bleeds/number of days during the efficacy period] x 365.25) on study versus pre-study in the NIS population who had previously participated in study BH29768 (NCT02476942). In this outcome measure, all bleeds are included, irrespective of treatment with coagulation factors, with the following exception: bleeds due to surgery/procedure are excluded. As &quot;all bleeds&quot; comprises both treated and non-treated bleeds, the 72-hour rule was implemented separately for treated and non-treated bleeds. For treated bleeds, the 72-hour rule was implemented exactly as defined for the &quot;treated bleeds&quot; outcome measure. For non-treated bleeds, the 72-hour rule was implemented by calculating a treatment-free period of 72 hours from the bleed itself.</div><br/>
            <li style="margin-top:0.7ex;">Cohort A: Intra-Participant Comparison of Percentage of Participants by Categorized Number of Treated Bleeds on Study Versus Pre-Study in Treated Participants &lt;12 Years of Age From the NIS Population [&nbsp;Time&nbsp;Frame:&nbsp;Up to 24 weeks in NIS BH29768 (NCT02476942) prior to study entry and from Baseline to 52 weeks on this study; At primary completion date, the median (min-max) duration of the efficacy period in the NIS population was 88.57 (55.9-92.6) weeks.&nbsp;]<div class="tr-indent2" style="margin-top:1ex;">This is an intra-participant comparison of the percentage of participants by categorized number of treated bleeds over the efficacy period on study versus pre-study in the NIS population who had previously participated in study BH29768 (NCT02476942). A &quot;treated bleed&quot; is a bleed directly followed by a hemophilia medication reported to be a &quot;treatment for bleed&quot;, irrespective of time between treatment and the preceding bleed. A bleed and first treatment thereafter are considered to be pairs, with the following exception: if multiple bleeds occur on the same calendar day, the subsequent treatment is considered to apply for each of these multiple bleeds. The 72-hour rule was implemented: two bleeds of the same type and at the same anatomical location are counted as one bleed if the second bleed occurs within 72 hours from the last treatment for the first bleed. Bleeds due to surgery/procedure are excluded.</div><br/>
            <li style="margin-top:0.7ex;">Cohort A: Intra-Participant Comparison of Percentage of Participants by Categorized Number of All Bleeds on Study Versus Pre-Study in Treated Participants &lt;12 Years of Age From the NIS Population [&nbsp;Time&nbsp;Frame:&nbsp;Up to 24 weeks in NIS BH29768 (NCT02476942) prior to study entry and from Baseline to 52 weeks on this study; At primary completion date, the median (min-max) duration of the efficacy period in the NIS population was 88.57 (55.9-92.6) weeks.&nbsp;]<div class="tr-indent2" style="margin-top:1ex;">This is an intra-participant comparison of the percentage of participants by categorized number of all bleeds over the efficacy period on study versus pre-study in the NIS population who had previously participated in study BH29768 (NCT02476942). In this outcome measure, all bleeds are included, irrespective of treatment with coagulation factors, with the following exception: bleeds due to surgery/procedure are excluded. As &quot;all bleeds&quot; comprises both treated and non-treated bleeds, the 72-hour rule was implemented separately for treated and non-treated bleeds. For treated bleeds, the 72-hour rule was implemented exactly as defined for the &quot;treated bleeds&quot; outcome measure. For non-treated bleeds, the 72-hour rule was implemented by calculating a treatment-free period of 72 hours from the bleed itself.</div><br/>
            <li style="margin-top:0.7ex;">Model-Based Annualized Bleed Rate (ABR) for Treated Bleeds in Treated Participants &#8805;12 Years of Age and &lt;40 kg Body Weight [&nbsp;Time&nbsp;Frame:&nbsp;From Baseline to 52 weeks&nbsp;]<div class="tr-indent2" style="margin-top:1ex;">The number of treated bleeds over the efficacy period is presented here as a model-based ABR that was analyzed using a negative binomial regression model with efficacy period as an offset to account for the difference in follow-up times. A bleed is considered a &quot;treated bleed&quot; if it is directly followed (i.e., no intervening bleed) by a hemophilia medication reported to be a &quot;treatment for bleed&quot;, irrespective of time between treatment and the preceding bleed. A bleed and the first treatment thereafter and before a new bleed starts, are considered to be pairs, with the following exception: if multiple bleeds occur on the same calendar day, the subsequent treatment is considered to apply for each of these multiple bleeds. The 72-hour rule was implemented: two bleeds of the same type and at the same anatomical location are counted as one bleed if the second bleed occurs within 72 hours from the last treatment for the first bleed. Bleeds due to surgery/procedure are excluded.</div><br/>
            <li style="margin-top:0.7ex;">Model-Based Annualized Bleed Rate (ABR) for All Bleeds in Treated Participants &#8805;12 Years of Age and &lt;40 kg Body Weight [&nbsp;Time&nbsp;Frame:&nbsp;From Baseline to 52 weeks&nbsp;]<div class="tr-indent2" style="margin-top:1ex;">The number of all bleeds over the efficacy period is presented as a model-based ABR that was analyzed using a negative binomial regression model with efficacy period as an offset to account for the difference in followup times (i.e., the time that each participant stays in the study). In this outcome measure, all bleeds are included, irrespective of treatment with coagulation factors, with the following exception: bleeds due to surgery/procedure are excluded. As &quot;all bleeds&quot; comprises both treated and non-treated bleeds, the 72-hour rule was implemented separately for treated and non-treated bleeds. For treated bleeds, the 72-hour rule was implemented exactly as defined for the &quot;treated bleeds&quot; outcome measure. For non-treated bleeds, the 72-hour rule was implemented by calculating a treatment-free period of 72 hours from the bleed itself.</div><br/>
            <li style="margin-top:0.7ex;">Median Calculated Annualized Bleed Rate (ABR) for Treated Bleeds in Treated Participants &#8805;12 Years of Age and &lt;40 kg Body Weight [&nbsp;Time&nbsp;Frame:&nbsp;From Baseline to 52 weeks&nbsp;]<div class="tr-indent2" style="margin-top:1ex;">The number of treated bleeds over the efficacy period is presented here as a calculated ABR that was annualized for each participant using the following formula: ABR = (number of bleeds/number of days during the efficacy period) x 365.25. A bleed is considered a &quot;treated bleed&quot; if it is directly followed (i.e., no intervening bleed) by a hemophilia medication reported to be a &quot;treatment for bleed&quot;, irrespective of time between treatment and the preceding bleed. A bleed and the first treatment thereafter and before a new bleed starts, are considered to be pairs, with the following exception: if multiple bleeds occur on the same calendar day, the subsequent treatment is considered to apply for each of these multiple bleeds. The 72-hour rule was implemented: two bleeds of the same type and at the same anatomical location are counted as one bleed if the second bleed occurs within 72 hours from the last treatment for the first bleed. Bleeds due to surgery/procedure are excluded.</div><br/>
            <li style="margin-top:0.7ex;">Median Calculated Annualized Bleed Rate (ABR) for All Bleeds in Treated Participants &#8805;12 Years of Age and &lt;40 kg Body Weight [&nbsp;Time&nbsp;Frame:&nbsp;From Baseline to 52 weeks&nbsp;]<div class="tr-indent2" style="margin-top:1ex;">The number of all bleeds over the efficacy period is presented here as a calculated ABR that was annualized for each participant using the following formula: ABR = (number of bleeds/number of days during the efficacy period) x 365.25. In this outcome measure, all bleeds are included, irrespective of treatment with coagulation factors, with the following exception: bleeds due to surgery/procedure are excluded. As &quot;all bleeds&quot; comprises both treated and non-treated bleeds, the 72-hour rule was implemented separately for treated and non-treated bleeds. For treated bleeds, the 72-hour rule was implemented exactly as defined for the &quot;treated bleeds&quot; outcome measure. For non-treated bleeds, the 72-hour rule was implemented by calculating a treatment-free period of 72 hours from the bleed itself.</div><br/>
            <li style="margin-top:0.7ex;">Number of Treated Bleeds Over Time in Participants With Dose Up-Titration [&nbsp;Time&nbsp;Frame:&nbsp;From Baseline to study completion (up to at least 52 weeks)&nbsp;]<div class="tr-indent2" style="margin-top:1ex;">The number of treated bleeds over time was to be analyzed in participants whose emicizumab maintenance dose was up-titrated to 3 mg/kg QW if they had experienced suboptimal bleeding control on emicizumab at steady-state, per protocol criteria. A bleed is considered a &quot;treated bleed&quot; if it is directly followed (i.e., no intervening bleed) by a hemophilia medication reported to be a &quot;treatment for bleed&quot;, irrespective of time between treatment and the preceding bleed. A bleed and the first treatment thereafter and before a new bleed starts, are considered to be pairs, with the following exception: if multiple bleeds occur on the same calendar day, the subsequent treatment is considered to apply for each of these multiple bleeds. The 72-hour rule was implemented: two bleeds of the same type and at the same anatomical location are counted as one bleed if the second bleed occurs within 72 hours from the last treatment for the first bleed. Bleeds due to surgery/procedure are excluded.</div><br/>
            <li style="margin-top:0.7ex;">Number of All Bleeds Over Time in Participants With Dose Up-Titration [&nbsp;Time&nbsp;Frame:&nbsp;From Baseline to study completion (up to at least 52 weeks)&nbsp;]<div class="tr-indent2" style="margin-top:1ex;">The number of all bleeds over time was to be analyzed in participants whose emicizumab maintenance dose was up-titrated to 3 mg/kg QW if they had experienced suboptimal bleeding control on emicizumab at steady-state, per protocol criteria. In this outcome measure, all bleeds are included, irrespective of treatment with coagulation factors, with the following exception: bleeds due to surgery/procedure are excluded. As &quot;all bleeds&quot; comprises both treated and non-treated bleeds, the 72-hour rule was implemented separately for treated and non-treated bleeds. For treated bleeds, the 72-hour rule was implemented exactly as defined for the &quot;treated bleeds&quot; outcome measure. For non-treated bleeds, the 72-hour rule was implemented by calculating a treatment-free period of 72 hours from the bleed itself.</div><br/>
            <li style="margin-top:0.7ex;">Long-Term Efficacy of Emicizumab in All Cohorts: Model-Based Annualized Bleed Rate (ABR) for Treated Bleeds, All Bleeds, Treated Spontaneous Bleeds, Treated Joint Bleeds, and Treated Target Joint Bleeds in Treated Participants &lt;12 Years of Age [&nbsp;Time&nbsp;Frame:&nbsp;From Baseline to study completion (median [min-max] duration of the efficacy periods in Cohorts A, B, and C were 92.29 [36.1-187.7] weeks, 68.21 [56.7-129.4] weeks, and 69.43 [8.9-144.3] weeks, respectively)&nbsp;]<div class="tr-indent2" style="margin-top:1ex;">The number of bleeds over the efficacy period was shown as a model-based ABR that used a negative binomial regression model with efficacy period as an offset to account for the difference in follow-up times. A bleed is considered a &quot;treated bleed&quot; if it is directly followed (i.e., no intervening bleed) by a hemophilia medication reported to be a &quot;treatment for bleed&quot;, irrespective of time between treatment and the preceding bleed. &quot;All bleeds&quot; included bleeds irrespective of treatment with coagulation factors, with the following exception: bleeds due to surgery/procedure are excluded. Bleeds are classified as &quot;spontaneous&quot; if there is no other known contributing factor such as trauma or procedure/surgery. A &quot;joint bleed&quot; is defined as a bleed occurring in a joint. A &quot;target joint bleed&quot; is defined as a joint bleed in a target joint (&#8805;3 bleeds have occurred over the last 24 weeks prior to study entry).</div><br/>
            <li style="margin-top:0.7ex;">Long-Term Efficacy of Emicizumab in All Cohorts: Mean Calculated Annualized Bleed Rate (ABR) for Treated Bleeds, All Bleeds, Treated Spontaneous Bleeds, Treated Joint Bleeds, and Treated Target Joint Bleeds in Treated Participants &lt;12 Years of Age [&nbsp;Time&nbsp;Frame:&nbsp;From Baseline to study completion (median [min-max] duration of the efficacy periods in Cohorts A, B, and C were 92.29 [36.1-187.7] weeks, 68.21 [56.7-129.4] weeks, and 69.43 [8.9-144.3] weeks, respectively)&nbsp;]<div class="tr-indent2" style="margin-top:1ex;">The number of treated bleeds over the efficacy period is presented here as a calculated ABR that was annualized for each participant using the following formula: ABR = (number of bleeds/number of days during the efficacy period) x 365.25. A bleed is considered a &quot;treated bleed&quot; if it is directly followed (i.e., no intervening bleed) by a hemophilia medication reported to be a &quot;treatment for bleed&quot;, irrespective of time between treatment and the preceding bleed. &quot;All bleeds&quot; included bleeds irrespective of treatment with coagulation factors, with the following exception: bleeds due to surgery/procedure are excluded. Bleeds are classified as &quot;spontaneous&quot; if there is no other known contributing factor such as trauma or procedure/surgery. A &quot;joint bleed&quot; is defined as a bleed with type reported as &quot;joint&quot;. A &quot;target joint bleed&quot; is defined as a joint bleed in a target joint, which is a joint location where at least 3 bleeds have occurred over the last 24 weeks prior to study entry.</div><br/>
            <li style="margin-top:0.7ex;">Long-Term Efficacy of Emicizumab in All Cohorts: Median Calculated Annualized Bleed Rate (ABR) for Treated Bleeds, All Bleeds, Treated Spontaneous Bleeds, Treated Joint Bleeds, and Treated Target Joint Bleeds in Treated Participants &lt;12 Years of Age [&nbsp;Time&nbsp;Frame:&nbsp;From Baseline to study completion (median [min-max] duration of the efficacy periods in Cohorts A, B, and C were 92.29 [36.1-187.7] weeks, 68.21 [56.7-129.4] weeks, and 69.43 [8.9-144.3] weeks, respectively)&nbsp;]<div class="tr-indent2" style="margin-top:1ex;">The number of treated bleeds over the efficacy period is presented here as a calculated ABR that was annualized for each participant using the following formula: ABR = (number of bleeds/number of days during the efficacy period) x 365.25. A bleed is considered a &quot;treated bleed&quot; if it is directly followed (i.e., no intervening bleed) by a hemophilia medication reported to be a &quot;treatment for bleed&quot;, irrespective of time between treatment and the preceding bleed. &quot;All bleeds&quot; included bleeds irrespective of treatment with coagulation factors, with the following exception: bleeds due to surgery/procedure are excluded. Bleeds are classified as &quot;spontaneous&quot; if there is no other known contributing factor such as trauma or procedure/surgery. A &quot;joint bleed&quot; is defined as a bleed with type reported as &quot;joint&quot;. A &quot;target joint bleed&quot; is defined as a joint bleed in a target joint, which is a joint location where at least 3 bleeds have occurred over the last 24 weeks prior to study entry.</div><br/>
            <li style="margin-top:0.7ex;">Change From Baseline Over Time in the Hemophilia-Specific Quality of Life Short Form (Haemo-QoL-SF) Questionnaire Total Score, as Completed by Treated Participants &#8805;8 to &lt;12 Years of Age [&nbsp;Time&nbsp;Frame:&nbsp;Baseline (Week 1), Weeks 13, 25, 37, 49, 57, 81, 105, 129, 153, and 177, and at study completion [SC] or early discontinuation [ED] (up to 188 weeks)&nbsp;]<div class="tr-indent2" style="margin-top:1ex;">The Haemo-QoL-SF is a self-reported questionnaire for children &#8805;8 years of age. It contains 35 items, which cover nine domains considered relevant for the children's health-related quality of life: Physical Health, Feelings, View of Yourself, Family, Friends, Other People, Sports and School, Dealing with Hemophilia, and Treatment. Items are rated with five respective response options: never, seldom, sometimes, often, and always. The Total Score is derived from the scores for all domains and ranges from 0 to 100, with a lower score reflective of better health-related quality of life.</div><br/>
            <li style="margin-top:0.7ex;">Change From Baseline Over Time in the Haemo-QoL-SF Questionnaire Physical Health Domain Score, as Completed by Treated Participants &#8805;8 to &lt;12 Years of Age [&nbsp;Time&nbsp;Frame:&nbsp;Baseline (Week 1), Weeks 13, 25, 37, 49, 57, 81, 105, 129, 153, and 177, and at study completion [SC] or early discontinuation [ED] (up to 188 weeks)&nbsp;]<div class="tr-indent2" style="margin-top:1ex;">The Haemo-QoL-SF is a self-reported questionnaire for children &#8805;8 years of age. It contains 35 items, which cover nine domains considered relevant for the children's health-related quality of life: Physical Health, Feelings, View of Yourself, Family, Friends, Other People, Sports and School, Dealing with Hemophilia, and Treatment. The Physical Health domain assesses hemophilia-related symptoms (painful swellings and presence of joint pain) and physical functioning (pain with movement). Items are rated with five respective response options: never, seldom, sometimes, often, and always. The Physical Health domain score ranges from 0 to 100, with a lower score reflective of better physical health.</div><br/>
            <li style="margin-top:0.7ex;">Change From Baseline Over Time in Caregiver-Reported Adapted Health-Related Quality of Life for Hemophilia Patients With Inhibitors Including Aspects of Caregiver Burden (Adapted Inhib-QoL) Questionnaire Total Score, Treated Participants &lt;12 Years of Age [&nbsp;Time&nbsp;Frame:&nbsp;Baseline (Week 1), Weeks 13, 25, 37, 49, 57, 81, 105, 129, 153, and 177, and at study completion [SC] or early discontinuation [ED] (up to 188 weeks)&nbsp;]<div class="tr-indent2" style="margin-top:1ex;">Proxy assessment of health-related quality of life (HRQoL) and aspects of caregiver burden were assessed using the Adapted Inhib-QoL questionnaire, which comprises two parts with a total of 30 questions. The first part asks the caregiver for his/her opinion on the child's HRQoL and consists of two scales: Physical Health and Treatment. The second part asks the caregiver to rate how the child's situation is for them (i.e., the impact of the child's disease and treatment on the caregiver) and consists of 6 scales (5 if the child does not have siblings): General Condition, Dealing with the Inhibitor, Perceive Treatment, Family life, Siblings, Contact with Others. Items are rated with five respective response options: never, seldom, sometimes, often, and all the time. The Total Score is derived from the individual scores of all of the domains and it ranges from 0 to 100, with lower scores reflective of better HRQoL.</div><br/>
            <li style="margin-top:0.7ex;">Change From Baseline Over Time in the Caregiver-Reported Adapted Inhib-QoL Questionnaire Physical Health Domain Score, Treated Participants &lt;12 Years of Age [&nbsp;Time&nbsp;Frame:&nbsp;Baseline (Week 1), Weeks 13, 25, 37, 49, 57, 81, 105, 129, 153, and 177, and at study completion [SC] or early discontinuation [ED] (up to 188 weeks)&nbsp;]<div class="tr-indent2" style="margin-top:1ex;">Proxy assessment of health-related quality of life (HRQoL) and aspects of caregiver burden were assessed using the Adapted Inhib-QoL questionnaire, which comprises two parts with a total of 30 questions. The first part asks the caregiver for his/her opinion on the child's HRQoL (proxy HRQoL) and consists of two scales: Physical Health and Treatment. The second part asks the caregiver to rate how the child's situation is for them (i.e., the impact of the child's disease and treatment on the caregiver) and consists of 6 scales (5 if the child does not have siblings): General Condition, Dealing with the Inhibitor, Perceive Treatment, Family Life, Siblings, Contact with Others. Items are rated with five respective response options: never, seldom, sometimes, often, and all the time. A total score is calculated as the sum of all of the items in the scale. The Physical Health domain score ranges from 0 to 100, with lower scores reflective of better physical health.</div><br/>
            <li style="margin-top:0.7ex;">Number of Participants With at Least One Adverse Event [&nbsp;Time&nbsp;Frame:&nbsp;From Baseline up to 24 weeks after study drug discontinuation; the median (min-max) observation periods in Cohorts A, B, and C were 96.93 (36.1-188.1) weeks, 68.21 (56.7-129.4) weeks, and 69.43 (38.9-144.3) weeks, respectively.&nbsp;]<div class="tr-indent2" style="margin-top:1ex;">The number of participants experiencing at least one adverse event, including all non-serious and serious adverse events, are reported.</div><br/>
            <li style="margin-top:0.7ex;">Number of Participants With at Least One Grade &#8805;3 Adverse Event [&nbsp;Time&nbsp;Frame:&nbsp;From Baseline up to 24 weeks after study drug discontinuation; the median (min-max) observation periods in Cohorts A, B, and C were 96.93 (36.1-188.1) weeks, 68.21 (56.7-129.4) weeks, and 69.43 (38.9-144.3) weeks, respectively.&nbsp;]<div class="tr-indent2" style="margin-top:1ex;">The World Health Organization (WHO) toxicity grading scale was used for assessing adverse event severity. For adverse events that are not specifically listed in the WHO toxicity grading scale, a grade 3 adverse event is defined as: severe, marked limitation in activity, some assistance usually required, medical intervention or therapy required, hospitalization possible; and a grade 4 adverse event is defined as: life-threatening, extreme limitation in activity, significant assistance required, significant medical intervention or therapy required, hospitalization or hospice care probable.</div><br/>
            <li style="margin-top:0.7ex;">Number of Participants With at Least One Adverse Event Leading to Withdrawal From Treatment [&nbsp;Time&nbsp;Frame:&nbsp;From Baseline up to 24 weeks after study drug discontinuation; the median (min-max) observation periods in Cohorts A, B, and C were 96.93 (36.1-188.1) weeks, 68.21 (56.7-129.4) weeks, and 69.43 (38.9-144.3) weeks, respectively.&nbsp;]<br/>
            <li style="margin-top:0.7ex;">Number of Participants With at Least One Adverse Event of Local Injection Site Reaction [&nbsp;Time&nbsp;Frame:&nbsp;From Baseline up to 24 weeks after study drug discontinuation; the median (min-max) observation periods in Cohorts A, B, and C were 96.93 (36.1-188.1) weeks, 68.21 (56.7-129.4) weeks, and 69.43 (38.9-144.3) weeks, respectively.&nbsp;]<div class="tr-indent2" style="margin-top:1ex;">Local adverse events that occurred within 24 hours after study drug administration and, in the investigator's opinion, were judged to be related to study drug injection, were captured as an &quot;injection-site reaction&quot; on the Adverse Event electronic Case Report Form (eCRF). An injection-related reaction that was localized was marked as a &quot;local injection-site reaction.&quot;</div><br/>
            <li style="margin-top:0.7ex;">Number of Participants With at Least One Adverse Event of Systemic Hypersensitivity, Anaphylaxis, or Anaphylactoid Reaction [&nbsp;Time&nbsp;Frame:&nbsp;From Baseline up to 24 weeks after study drug discontinuation; the median (min-max) observation periods in Cohorts A, B, and C were 96.93 (36.1-188.1) weeks, 68.21 (56.7-129.4) weeks, and 69.43 (38.9-144.3) weeks, respectively.&nbsp;]<div class="tr-indent2" style="margin-top:1ex;">Systemic hypersensitivity, anaphylaxis, or anaphylactoid reactions were identified by the investigator using Sampson's criteria, as defined in the protocol. At the primary completion date, one participant had reported two non-serious adverse events (cough and abdominal pain) that were identified as a potential case based on a Standardised MedDRA Queries (SMQ) search for Sampson's criteria. However, after medical review of the case, it was confirmed that this case was not indicative of a systemic hypersensitivity, anaphylaxis, or anaphylactoid reaction.</div><br/>
            <li style="margin-top:0.7ex;">Number of Participants With at Least One Adverse Event of Thromboembolic Event [&nbsp;Time&nbsp;Frame:&nbsp;From Baseline up to 24 weeks after study drug discontinuation; the median (min-max) observation periods in Cohorts A, B, and C were 96.93 (36.1-188.1) weeks, 68.21 (56.7-129.4) weeks, and 69.43 (38.9-144.3) weeks, respectively.&nbsp;]<br/>
            <li style="margin-top:0.7ex;">Number of Participants With at Least One Adverse Event of Thrombotic Microangiopathy [&nbsp;Time&nbsp;Frame:&nbsp;From Baseline up to 24 weeks after study drug discontinuation; the median (min-max) observation periods in Cohorts A, B, and C were 96.93 (36.1-188.1) weeks, 68.21 (56.7-129.4) weeks, and 69.43 (38.9-144.3) weeks, respectively.&nbsp;]<br/>
            <li style="margin-top:0.7ex;">Number of Participants Testing Negative or Positive for the Presence of Anti-Drug Antibodies (ADAs), Including Neutralizing ADAs, During the Study [&nbsp;Time&nbsp;Frame:&nbsp;Predose (0 hour) at Weeks 1, 5, 17, 33, 49, 57; then every 12 weeks until study completion (up to 188 weeks)&nbsp;]<div class="tr-indent2" style="margin-top:1ex;">'Total ADA Negative' is the sum of all subjects who tested negative for ADA in the 2 following categories: 'ADA Negative', those who are pre-dose ADA negative or are missing pre-dose ADA data and who have all negative post-dose ADA results; and 'ADA Negative (Treatment Unaffected)', a subset who are pre-dose ADA positive but do not have a &#8805;4-fold increase in post-dose ADA levels compared to baseline measurement. 'Total ADA Positive' is the sum of all subjects who tested positive for ADA in the 2 following categories: 'ADA Positive (Treatment Boosted)', those who are pre-dose ADA positive and have a &#8805;4-fold increase in post-dose ADA levels compared to baseline measurement; and 'ADA Positive (Treatment Induced)', those who are pre-dose ADA negative or missing data and who have at least one post-dose ADA positive sample. ADA-positive samples were further analyzed for neutralizing capacity using a modified FVIII chromogenic assay; if also positive, they were considered neutralizing ADAs.</div><br/>
            <li style="margin-top:0.7ex;">Number of Participants by Hematology Parameter Laboratory Test Results as a Shift From Baseline to Highest WHO Grade Post-Baseline [&nbsp;Time&nbsp;Frame:&nbsp;From Baseline until study completion (up to 188 weeks)&nbsp;]<div class="tr-indent2" style="margin-top:1ex;">The World Health Organization (WHO) toxicity grading scale was used for determining the severity of laboratory abnormalities (i.e., test results outside of the reference range) for hematology parameters; Grade 0 is normal and Grades 1 to 4 represent worsening levels of the parameter outside of the normal range in the specified direction of the abnormality (high and low are above and below the range, respectively). Not every laboratory abnormality qualified as an adverse event (AE). A laboratory test result was reported as an AE if it met any of the following criteria: was accompanied by clinical symptoms; resulted in a change in study treatment; resulted in a medical intervention or a change in concomitant therapy; or was clinically significant in the investigator's judgment. Baseline was defined as the last available assessment prior to first receipt of study drug. Abs = absolute count</div><br/>
            <li style="margin-top:0.7ex;">Number of Participants by Chemistry Parameter Laboratory Test Results as a Shift From Baseline to Highest WHO Grade Post-Baseline [&nbsp;Time&nbsp;Frame:&nbsp;From Baseline until study completion (up to 188 weeks)&nbsp;]<div class="tr-indent2" style="margin-top:1ex;">The World Health Organization (WHO) toxicity grading scale was used for determining the severity of laboratory abnormalities (i.e., test results outside of the reference range) for chemistry parameters; Grade 0 is normal and Grades 1 to 4 represent worsening levels of the parameter outside of the normal range in the specified direction of the abnormality (high and low are above and below the range, respectively). Not every laboratory abnormality qualified as an adverse event (AE). A laboratory test result was reported as an AE if it met any of the following criteria: was accompanied by clinical symptoms; resulted in a change in study treatment; resulted in a medical intervention or a change in concomitant therapy; or was clinically significant in the investigator's judgment. Baseline was defined as the last available assessment prior to first receipt of study drug. SGOT/AST = aspartate aminotransferase; SGPT/ALT = alanine aminotransferase</div><br/>
            <li style="margin-top:0.7ex;">Plasma Trough Concentration (Ctrough) of Emicizumab [&nbsp;Time&nbsp;Frame:&nbsp;Predose (0 hour) at Weeks 1, 2, 3, 4, 5, 7, 9, 13, 17, 21, 25, 29, 33, 37, 41, 49, 57, 69, 81, 93, 105, 117, 129, 141, 153, 165, and 177&nbsp;]<div class="tr-indent2" style="margin-top:1ex;">Pre-dose (trough) plasma concentrations of emicizumab were analyzed using a validated enzyme-linked immunosorbent assay (ELISA). The lower limit of quantitation was 0.1 micrograms per milliliter (&#956;g/mL).</div><br/>
            </ol>
    </div>
    <br/>
    
    
    
  </div>
  
			  
<!-- eligibility_section -->
<div class="tr-indent1" style="margin-top:3ex; border:1px solid white">
<div class="tr-subsection">
	<div class="ct-header2"><a id="eligibility"></a>Eligibility Criteria</div>
	<div class="tr-underline"></div>
	<div class="tr-dropdown" style="padding-right:10em">
Go&nbsp;to&nbsp;
<button class="tr-dropbtn" style="font-weight:bold; font-size:14px">
<img src="/ct2/html/images/pulldown.png" alt="sections">
</button>

  <div class="tr-dropdown-content">
	<a href="#wrapper">Top of Page</a>
    <a href="#studydesc">Study Description</a>
    <a href="#studydesign">Study Design</a>

    <!-- arms and groups table -->
        <a href="#armgroup">Arms and Interventions</a>
    
        <a href="#outcomemeasures">Outcome Measures</a>
        <a href="#eligibility">Eligibility Criteria</a>
    <a href="#contactlocation">Contacts and Locations</a>
    <a href="#moreinfo">More Information</a>
  </div>
</div>
</div>
<br/>

<p>
  <div class="tr-indent2 usa-alert usa-alert-warning nlm-info">
    <strong>Information from the National Library of Medicine</strong>
    <img src="/ct2/html/images/NIH_NLM_ABRV_BLK_4.png" style="width:5em; float:right;" alt=""/>
    <p>
    <p>
    <em>Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, <a href="/ct2/about-studies/learn" title="Learn About Clinical Studies"><u>Learn About Clinical Studies.</u></a>
    </em>
  </div>


  <br/>
  <div class="tr-indent2">
    <table class="ct-layout_table tr-tableStyle tr-studyInfo">
      <caption>Layout table for eligibility information</caption>
      <thead>
        <tr>
          <th id="elgType"></th>
          <th id="elgData"></th>
        </tr>
      </thead>
      <tbody>
            <tr>
        <td headers="elgType" class="ct-nowrap">Ages Eligible for Study: &nbsp; </td>
        <td headers="elgData" style="padding-left:1em">up to 17 Years &nbsp; (Child)</td>
      </tr>
                  <tr>
        <td headers="elgType" class="ct-nowrap">Sexes Eligible for Study: &nbsp; </td>
        <td headers="elgData" style="padding-left:1em">All</td>
      </tr>
                              <tr>
        <td headers="elgType" class="ct-nowrap">Accepts Healthy Volunteers: &nbsp; </td>
        <td headers="elgData" style="padding-left:1em">No</td>
      </tr>
                  </tbody>
    </table>

    
        <div class="ct-header3" style="margin-top:2ex">Criteria</div>
    <div class="tr-indent2"><p style="margin-top:1ex; margin-bottom:1ex;">Inclusion Criteria:</p>
  <ul style="margin-top:1ex; margin-bottom:1ex;">
    <li style="margin-top:0.7ex;">Children less than (&lt;) 12 years of age, with allowance for participants 12 to 17 years of age who weigh &lt;40 kilograms (kg) (Cohort A only); and participants &lt;2 years of age will be allowed to participate only after the protocol-defined interim data review criteria are met (Cohort A only)</li>
    <li style="margin-top:0.7ex;">Diagnosis of congenital hemophilia A of any severity and documented history of high-titer inhibitor (that is [i.e.], greater than or equal to [&gt;/=] 5 bethesda units [BU])</li>
    <li style="margin-top:0.7ex;">Requires treatment with bypassing agents</li>
    <li style="margin-top:0.7ex;">Adequate hematologic, hepatic, and renal function</li>
  </ul>
  <p style="margin-top:0ex; margin-bottom:1ex;">Exclusion Criteria:</p>
  <ul style="margin-top:1ex; margin-bottom:1ex;">
    <li style="margin-top:0.7ex;">Inherited or acquired bleeding disorder other than hemophilia A</li>
    <li style="margin-top:0.7ex;">Ongoing (or planning to receive during the study) immune tolerance induction (ITI) therapy or prophylaxis treatment with FVIII</li>
    <li style="margin-top:0.7ex;">Previous (in the past 12 months) or current treatment for thromboembolic disease or signs of thromboembolic disease</li>
    <li style="margin-top:0.7ex;">Other disease that may increase risk of bleeding or thrombosis</li>
    <li style="margin-top:0.7ex;">History of clinically significant hypersensitivity associated with monoclonal antibody therapy or components of the emicizumab injection</li>
    <li style="margin-top:0.7ex;">Known infection with human immunodeficiency virus (HIV) or hepatitis B or C virus</li>
    <li style="margin-top:0.7ex;">Use of systemic immunomodulators at enrollment or planned use during the study period</li>
    <li style="margin-top:0.7ex;">Planned surgery (excluding minor procedures such as tooth extraction or incision and drainage) during the study</li>
    <li style="margin-top:0.7ex;">Inability (or unwillingness by caregiver) to receive (allow receipt of) blood or blood products (or any standard-of-care treatment for a life-threatening condition)</li>
    <li style="margin-top:0.7ex;">Participants who are at high risk for thrombotic microangiopathy (TMA) (e.g., have a previous medical or family history of TMA), in the investigator's judgement</li>
  </ul></div>
    
  </div>

  </div>

			  
<!-- location_section -->
<a id="contacts"></a>
<div class="tr-indent1" style="margin-top:3ex">
<div class="tr-subsection">
	<div class="ct-header2"><a id="contactlocation"></a>Contacts and Locations</div>
	<div class="tr-underline"></div>
	<div class="tr-dropdown" style="padding-right:10em">
Go&nbsp;to&nbsp;
<button class="tr-dropbtn" style="font-weight:bold; font-size:14px">
<img src="/ct2/html/images/pulldown.png" alt="sections">
</button>

  <div class="tr-dropdown-content">
	<a href="#wrapper">Top of Page</a>
    <a href="#studydesc">Study Description</a>
    <a href="#studydesign">Study Design</a>

    <!-- arms and groups table -->
        <a href="#armgroup">Arms and Interventions</a>
    
        <a href="#outcomemeasures">Outcome Measures</a>
        <a href="#eligibility">Eligibility Criteria</a>
    <a href="#contactlocation">Contacts and Locations</a>
    <a href="#moreinfo">More Information</a>
  </div>
</div>
</div>
<br/>


<div class="tr-indent2" style="margin-top:2ex">

<!--
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. 
To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. 
For general information, see <a href="/ct2/about-studies/learn" target="def_win" onClick="openNewWindow('/ct2/about-studies/learn'); return false;" title="Learn About Clinical Studies - opens new window"><u>Learn About Clinical Studies.</u></a>
<br/>
-->

  
  <div class="usa-alert usa-alert-warning nlm-info">
    <strong>Information from the National Library of Medicine</strong>
    <img src="/ct2/html/images/NIH_NLM_ABRV_BLK_4.png" style="width:5em; float:right;" alt=""/>
    <p>
    <p>
    <em>
    To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
    </em>
    <p>
    <em>
    Please refer to this study by its ClinicalTrials.gov identifier (NCT number): <strong>NCT02795767</strong>
    </em>
  </div>
  <br/>

  <!-- contacts -->
  
  <!-- locations -->
   <a id="locn"></a>
  <div class="ct-header3" style="margin-top:2ex;margin-bottom:2ex;">Locations</div>

      <script type="text/javascript" async src="/ct2/html/js/ExpandCollapseScript.js"></script>
    
    <span id="EXPAND_CONTROL-Locations" class="EXPAND tr-showAndHide"       onclick="toggleSectionAndControls('-Locations');document.getElementById('locn').scrollIntoView({behavior: 'smooth', block: 'start'});" 
      title="Show 28 study locations">
      <img src="/ct2/html/images/expand.png" alt="Show">
      <span style="padding-bottom:3px"> Show 28 study locations</span>
    </span>
    <span  id="COLLAPSE_CONTROL-Locations" class="COLLAPSE tr-showAndHide" style="display:none"      onclick="toggleSectionAndControls('-Locations');" 
      title="Hide 28 study locations">
      <img src="/ct2/html/images/collapse.png"  alt="Hide">
      <span style="padding-bottom:3px"> Hide 28 study locations</span>
    </span>
     
  <div id="COLLAPSE-Locations" class="COLLAPSE" style="display:none">
        <div class="tr-table_cover">
      <table class="ct-layout_table tr-indent2">
        <caption>Layout table for location information</caption>
        <thead>
          <tr>
            <th id="locName"></th>
            <th id="locStatus"></th>
          </tr>
        </thead>
        <tbody>
                                    <tr><td colspan="2" class="ct-header3" style="padding-top:2ex;">United States, California</td></tr>
                                      <tr>
                            <td headers="locName" style="padding-left:2em;">Children's Hospital Los Angeles</td>
                                          <td headers="locStatus"></td>
                          </tr>
                          <tr><td colspan="2" style="padding:0;padding-left:4em;">Los Angeles, California, United States, 90010  </td></tr>
                                                            <tr><td colspan="2" class="ct-header3" style="padding-top:2ex;">United States, Colorado</td></tr>
                                      <tr>
                            <td headers="locName" style="padding-left:2em;">University of Colorado Denver, Children's Hospital</td>
                                          <td headers="locStatus"></td>
                          </tr>
                          <tr><td colspan="2" style="padding:0;padding-left:4em;">Aurora, Colorado, United States, 80045  </td></tr>
                                                            <tr><td colspan="2" class="ct-header3" style="padding-top:2ex;">United States, Georgia</td></tr>
                                      <tr>
                            <td headers="locName" style="padding-left:2em;">Children'S Healthcare of Atlanta</td>
                                          <td headers="locStatus"></td>
                          </tr>
                          <tr><td colspan="2" style="padding:0;padding-left:4em;">Atlanta, Georgia, United States, 30322  </td></tr>
                                                            <tr><td colspan="2" class="ct-header3" style="padding-top:2ex;">United States, Illinois</td></tr>
                                      <tr>
                            <td headers="locName" style="padding-left:2em;">Rush Medical Center</td>
                                          <td headers="locStatus"></td>
                          </tr>
                          <tr><td colspan="2" style="padding:0;padding-left:4em;">Chicago, Illinois, United States, 60612  </td></tr>
                                                            <tr><td colspan="2" class="ct-header3" style="padding-top:2ex;">United States, Michigan</td></tr>
                                      <tr>
                            <td headers="locName" style="padding-left:2em;">Children's Hospital of Michigan; Pediatrics</td>
                                          <td headers="locStatus"></td>
                          </tr>
                          <tr><td colspan="2" style="padding:0;padding-left:4em;">Detroit, Michigan, United States, 48201  </td></tr>
                                                            <tr><td colspan="2" class="ct-header3" style="padding-top:2ex;">United States, New York</td></tr>
                                      <tr>
                            <td headers="locName" style="padding-left:2em;">North Shore/Long Island Jewish PRIME; Pediatric Hematology/Oncology &amp; Stem Cell Transplantation</td>
                                          <td headers="locStatus"></td>
                          </tr>
                          <tr><td colspan="2" style="padding:0;padding-left:4em;">New Hyde Park, New York, United States, 11040  </td></tr>
                                                            <tr><td colspan="2" class="ct-header3" style="padding-top:2ex;">United States, Oregon</td></tr>
                                      <tr>
                            <td headers="locName" style="padding-left:2em;">Oregon Health &amp; Science Uni ; Dept of Pediatrics</td>
                                          <td headers="locStatus"></td>
                          </tr>
                          <tr><td colspan="2" style="padding:0;padding-left:4em;">Portland, Oregon, United States, 97201  </td></tr>
                                                            <tr><td colspan="2" class="ct-header3" style="padding-top:2ex;">United States, Washington</td></tr>
                                      <tr>
                            <td headers="locName" style="padding-left:2em;">Bloodworks Northwest (formerly Puget Sound Blood Center); Hemophilia</td>
                                          <td headers="locStatus"></td>
                          </tr>
                          <tr><td colspan="2" style="padding:0;padding-left:4em;">Seattle, Washington, United States, 98104  </td></tr>
                                                            <tr><td colspan="2" class="ct-header3" style="padding-top:2ex;">Costa Rica</td></tr>
                                      <tr>
                            <td headers="locName" style="padding-left:2em;">ICIC</td>
                                          <td headers="locStatus"></td>
                          </tr>
                          <tr><td colspan="2" style="padding:0;padding-left:4em;">San Jose, Costa Rica, 1000  </td></tr>
                                                            <tr><td colspan="2" class="ct-header3" style="padding-top:2ex;">France</td></tr>
                                      <tr>
                            <td headers="locName" style="padding-left:2em;">Hopital Cardio-vasculaire Louis Pradel; Hemostase clinique</td>
                                          <td headers="locStatus"></td>
                          </tr>
                          <tr><td colspan="2" style="padding:0;padding-left:4em;">Bron, France, 69677  </td></tr>
                                                          <tr>
                            <td headers="locName" style="padding-left:2em;">CH de Bicetre; Centre de Traitement d' Hemophilie</td>
                                          <td headers="locStatus"></td>
                          </tr>
                          <tr><td colspan="2" style="padding:0;padding-left:4em;">Le Kremlin Bicetre, France, 94275  </td></tr>
                                                          <tr>
                            <td headers="locName" style="padding-left:2em;">Groupe Hospitalier Necker Enfants Malades</td>
                                          <td headers="locStatus"></td>
                          </tr>
                          <tr><td colspan="2" style="padding:0;padding-left:4em;">Paris, France, 75015  </td></tr>
                                                            <tr><td colspan="2" class="ct-header3" style="padding-top:2ex;">Germany</td></tr>
                                      <tr>
                            <td headers="locName" style="padding-left:2em;">Universit&#228;tsklinikum Bonn; Institut f&#252;r Experimentelle H&#228;matologie und Transfusionsmedizin</td>
                                          <td headers="locStatus"></td>
                          </tr>
                          <tr><td colspan="2" style="padding:0;padding-left:4em;">Bonn, Germany, 53127  </td></tr>
                                                            <tr><td colspan="2" class="ct-header3" style="padding-top:2ex;">Italy</td></tr>
                                      <tr>
                            <td headers="locName" style="padding-left:2em;">IRCCS Ca' Granda Ospedale Maggiore Policlinico; Centro Emofilia e Trombosi &quot;Angelo Bianchi e Bonomi&quot;</td>
                                          <td headers="locStatus"></td>
                          </tr>
                          <tr><td colspan="2" style="padding:0;padding-left:4em;">Milano, Lombardia, Italy, 20122  </td></tr>
                                                            <tr><td colspan="2" class="ct-header3" style="padding-top:2ex;">Japan</td></tr>
                                      <tr>
                            <td headers="locName" style="padding-left:2em;">Nagoya University Hospital</td>
                                          <td headers="locStatus"></td>
                          </tr>
                          <tr><td colspan="2" style="padding:0;padding-left:4em;">Aichi, Japan, 466-8560  </td></tr>
                                                          <tr>
                            <td headers="locName" style="padding-left:2em;">Hospital of the University of Occupational and Environmental Health,Japan</td>
                                          <td headers="locStatus"></td>
                          </tr>
                          <tr><td colspan="2" style="padding:0;padding-left:4em;">Kitakyushu-shi, Japan, 807-8556  </td></tr>
                                                          <tr>
                            <td headers="locName" style="padding-left:2em;">Nara Medical University Hospital</td>
                                          <td headers="locStatus"></td>
                          </tr>
                          <tr><td colspan="2" style="padding:0;padding-left:4em;">Nara, Japan, 634-8522  </td></tr>
                                                          <tr>
                            <td headers="locName" style="padding-left:2em;">Shizuoka Children's Hospital</td>
                                          <td headers="locStatus"></td>
                          </tr>
                          <tr><td colspan="2" style="padding:0;padding-left:4em;">Shizuoka, Japan, 420-8660  </td></tr>
                                                          <tr>
                            <td headers="locName" style="padding-left:2em;">Ogikubo Hospital</td>
                                          <td headers="locStatus"></td>
                          </tr>
                          <tr><td colspan="2" style="padding:0;padding-left:4em;">Tokyo, Japan, 167-0035  </td></tr>
                                                            <tr><td colspan="2" class="ct-header3" style="padding-top:2ex;">South Africa</td></tr>
                                      <tr>
                            <td headers="locName" style="padding-left:2em;">Charlotte Maxeke Johannesburg Hospital; Haemophilia Comprehensive Care Center</td>
                                          <td headers="locStatus"></td>
                          </tr>
                          <tr><td colspan="2" style="padding:0;padding-left:4em;">Johannesburg, South Africa, 2193  </td></tr>
                                                            <tr><td colspan="2" class="ct-header3" style="padding-top:2ex;">Spain</td></tr>
                                      <tr>
                            <td headers="locName" style="padding-left:2em;">Hospital Universitario la Paz; Servicio de Hematologia</td>
                                          <td headers="locStatus"></td>
                          </tr>
                          <tr><td colspan="2" style="padding:0;padding-left:4em;">Madrid, Spain, 28046  </td></tr>
                                                          <tr>
                            <td headers="locName" style="padding-left:2em;">Hospital Universitario Virgen del Rocio; Servicio de Hematologia</td>
                                          <td headers="locStatus"></td>
                          </tr>
                          <tr><td colspan="2" style="padding:0;padding-left:4em;">Sevilla, Spain, 41013  </td></tr>
                                                          <tr>
                            <td headers="locName" style="padding-left:2em;">Hospital Universitario la Fe; Servicio de Hematologia</td>
                                          <td headers="locStatus"></td>
                          </tr>
                          <tr><td colspan="2" style="padding:0;padding-left:4em;">Valencia, Spain, 46026  </td></tr>
                                                            <tr><td colspan="2" class="ct-header3" style="padding-top:2ex;">Turkey</td></tr>
                                      <tr>
                            <td headers="locName" style="padding-left:2em;">Adana Acibadem Hospital; Pediatric Hematology</td>
                                          <td headers="locStatus"></td>
                          </tr>
                          <tr><td colspan="2" style="padding:0;padding-left:4em;">Adana, Turkey, 01130  </td></tr>
                                                          <tr>
                            <td headers="locName" style="padding-left:2em;">Istanbul Uni Istanbul Medical Faculty</td>
                                          <td headers="locStatus"></td>
                          </tr>
                          <tr><td colspan="2" style="padding:0;padding-left:4em;">Istanbul, Turkey, 34093  </td></tr>
                                                          <tr>
                            <td headers="locName" style="padding-left:2em;">Istanbul University, Cerrahpasa Medical Faculty; Pediatrics Department</td>
                                          <td headers="locStatus"></td>
                          </tr>
                          <tr><td colspan="2" style="padding:0;padding-left:4em;">Istanbul, Turkey, 34098  </td></tr>
                                                          <tr>
                            <td headers="locName" style="padding-left:2em;">Ege University, School of Medicine; Pediatrics Department</td>
                                          <td headers="locStatus"></td>
                          </tr>
                          <tr><td colspan="2" style="padding:0;padding-left:4em;">Izmir, Turkey, 35100  </td></tr>
                                                            <tr><td colspan="2" class="ct-header3" style="padding-top:2ex;">United Kingdom</td></tr>
                                      <tr>
                            <td headers="locName" style="padding-left:2em;">Great Ormond street Hospital for Children NHS Foundation Trust; Haemophilia Centre</td>
                                          <td headers="locStatus"></td>
                          </tr>
                          <tr><td colspan="2" style="padding:0;padding-left:4em;">London, United Kingdom, WC1N 3HR  </td></tr>
                                          </tbody>
      </table>
    </div>
  </div>   
  
  <!-- sponsors -->
      <div class="ct-header3" style="margin-top:2ex">Sponsors and Collaborators</div>
              <div class="tr-indent2" style="margin-top:1ex">Hoffmann-La Roche</div>
              <div class="tr-indent2" style="margin-top:1ex">Chugai Pharmaceutical</div>
        
  <!-- overall officials -->
    <div class="ct-header3" style="margin-top:2ex">Investigators</div>
  <div class="tr-table_cover">
  <table class="ct-layout_table tr-indent2">
    <caption>Layout table for investigator information</caption>
    <thead>
    <tr>
      <th id="role" style="visibility:hidden"></th>
      <th id="name" style="visibility:hidden"></th>
      <th id="affiliation" style="visibility:hidden"></th>
      <th id="address" style="visibility:hidden"></th>
    </tr>
    </thead>
        <tr>
      <td headers="role">Study Director:</td>
      <td headers="name">Clinical Trials</td>
            <td headers="affiliation">Hoffmann-La Roche</td>
            <td headers="address"></td>
    </tr>
      </table>
  </div>
  

</div>
</div>
						
<!-- more_info_section -->

<!-- Large docs section -->

    <div class="tr-indent1" style="margin-top:5ex; border:1px solid white">
    <span class="ct-header2">&nbsp; Study Documents (Full-Text)</span>

    <div class="tr-indent2">
      <br/>
      Documents provided by Hoffmann-La Roche:
            <div class="tr-indent2" style="margin-top:2ex">
        <a class="tr-study-link" href="/ProvidedDocs/67/NCT02795767/Prot_000.pdf" title="Study Protocol" onclick="openNewWindow('/ProvidedDocs/67/NCT02795767/Prot_000.pdf'); return false">Study Protocol</a>&nbsp; [PDF] September 1, 2017
      </div>
            <div class="tr-indent2" style="margin-top:2ex">
        <a class="tr-study-link" href="/ProvidedDocs/67/NCT02795767/SAP_001.pdf" title="Statistical Analysis Plan" onclick="openNewWindow('/ProvidedDocs/67/NCT02795767/SAP_001.pdf'); return false">Statistical Analysis Plan</a>&nbsp; [PDF] March 14, 2018
      </div>
                 <br/>
    </div>
  </div>
    

<!-- More info section -->
  <div class="tr-indent1" style="margin-top:3ex; border:1px solid white">
  <div class="tr-subsection">
  	<div class="ct-header2"><a id="moreinfo"></a>More Information</div>
  	<div class="tr-underline"></div>
  	<div class="tr-dropdown" style="padding-right:10em">
Go&nbsp;to&nbsp;
<button class="tr-dropbtn" style="font-weight:bold; font-size:14px">
<img src="/ct2/html/images/pulldown.png" alt="sections">
</button>

  <div class="tr-dropdown-content">
	<a href="#wrapper">Top of Page</a>
    <a href="#studydesc">Study Description</a>
    <a href="#studydesign">Study Design</a>

    <!-- arms and groups table -->
        <a href="#armgroup">Arms and Interventions</a>
    
        <a href="#outcomemeasures">Outcome Measures</a>
        <a href="#eligibility">Eligibility Criteria</a>
    <a href="#contactlocation">Contacts and Locations</a>
    <a href="#moreinfo">More Information</a>
  </div>
</div>
  </div>
  
  <div class="tr-indent2" style="margin-top:1em;">


    <!-- Additional Information -->
    

    <!-- Available Study Data/Document -->
    

  <!-- References -->
    
    
  <!-- Derived References -->
        <span class="ct-header3">Publications automatically indexed to this study by ClinicalTrials.gov Identifier (NCT Number):</span>
      <div class="tr-indent2">
                <div style="margin-top:2ex">
                    <a href="/ct2/bye/rQoPWwoRrXS9-i-wudNgpQDxudhWudNzlXNiZip9Ei7ym67VZRFjcKCwOR4jA6h9Ei4L3BUgWwNG0it." title="Young G, Liesner R, Chang T, Sidonio R, Oldenburg J, Jim&#233;nez-Yuste V, Mahlangu J, Kruse-Jarres R, Wang M, Uguen M, Doral MY, Wright LY, Schmitt C, Levy GG, Shima M, Mancuso ME. A multicenter, open-label phase 3 study of emicizumab prophylaxis in children with hemophilia A with inhibitors. Blood. 2019 Dec 12;134(24):2127-2138. doi: 10.1182/blood.2019001869." onclick="openNewWindow('/ct2/bye/rQoPWwoRrXS9-i-wudNgpQDxudhWudNzlXNiZip9Ei7ym67VZRFjcKCwOR4jA6h9Ei4L3BUgWwNG0it.'); return false">Young G, Liesner R, Chang T, Sidonio R, Oldenburg J, Jim&#233;nez-Yuste V, Mahlangu J, Kruse-Jarres R, Wang M, Uguen M, Doral MY, Wright LY, Schmitt C, Levy GG, Shima M, Mancuso ME. A multicenter, open-label phase 3 study of emicizumab prophylaxis in children with hemophilia A with inhibitors. Blood. 2019 Dec 12;134(24):2127-2138. doi: 10.1182/blood.2019001869.</a>
                            </div>
              </div>
      <br/>
    
   
  <table class="ct-layout_table tr-tableStyle tr-moreInfo" style="margin-top:1ex;">
    <caption>Layout table for additonal information</caption>
    <thead>
    <tr>
      <th id="colTitle1"></th>
      <th id="colData1"></th>
    </tr>
    </thead>
    <tbody>
        <tr>
      <td headers="colTitle1" class="ct-nowrap">Responsible Party:</td>
      <td headers="colData1" style="padding-left:1em">Hoffmann-La Roche</td>
    </tr>
        <tr>
      <td headers="colTitle1" class="ct-nowrap">ClinicalTrials.gov Identifier:</td>
      <td headers="colData1" style="padding-left:1em">
        <a class="tr-study-link" title="Current version of study NCT02795767 on ClinicalTrials.gov" href="https://clinicaltrials.gov/show/NCT02795767">NCT02795767</a> &nbsp; &nbsp;

  <script type="text/javascript">
    <!--
    // Scramble access to archive site -
    // don't want crawlers directing users to outdated versions of the study
    // this should be opaque to crawlers that don't execute javascript
    var yyy=new Array(
      ['<','a clas','s="tr-study','-link c', 't-now','rap" t','itle="Hist','orical vers','ions of '],
      ['study ','NCT02795767',' on Clin','icalTrials.','go'],
      ['v Ar','chive',' Sit','e" ','onc','lick="','openN','ewWin', 'dow(','\'/ct2/', 'history/'],
      ['NCT02795767','\'); return', ' false;" '],
      ['href','="/ct2/','history/','NCT02795767"','>'],
      ['Histo','ry of C','hange','s<','/','a>']);
    var i=0;
    var j=0;
    var xxx='';
    for (i=0; i<yyy.length; i++)
      for (j=0; j<yyy[i].length; j++)
        xxx+=yyy[i][j];
    document.write(xxx)
    -->
  </script>

      </td>
    </tr>
            <tr>
      <td headers="colTitle1" class="ct-nowrap">Other Study ID Numbers:</td>
      <td headers="colData1" style="padding-left:1em">
                                    BH29992 <br/>
                                                2016-000073-21 ( EudraCT Number )<br/>
                            </td>
    </tr>
            <tr>
      <td headers="colTitle1" class="ct-nowrap">First Posted:</td>
      <td headers="colData1" style="padding-left:1em">June 10, 2016
          &nbsp;&nbsp;
          <a class="tr-study-link ct-nowrap" href="/ct2/keydates/NCT02795767"
                title="View key record dates for NCT02795767"
                onclick="openNewWindow('/ct2/keydates/NCT02795767'); return false;">Key Record Dates</a>
      </td>
    </tr>
            <tr>
      <td headers="colTitle1" class="ct-nowrap">Results First Posted:</td>
      <td headers="colData1" style="padding-left:1em">April 10, 2019</td>
    </tr>
        <tr>
      <td headers="colTitle1" class="ct-nowrap">Last Update Posted:</td>
      <td headers="colData1" style="padding-left:1em">June 2, 2021
      </td>
    </tr>
        <tr>
      <td headers="colTitle1" class="ct-nowrap">Last Verified:</td>
      <td headers="colData1" style="padding-left:1em">May 2021
      </td>
    </tr>
           
    <!-- Plan to Share Data -->
          <tr>
        <td headers="colTitle1" class="ct-nowrap" colspan="2" style="padding-top:3ex;">Individual Participant Data (IPD) Sharing Statement:</td>
      </tr>
      <tr>
        <td headers="colTitle1" class="ct-nowrap" style="padding-left:1em;">Plan to Share IPD:</td>
        <td headers="colData1" style="padding-left:1em">Yes</td>
      </tr>
            <tr>
        <td headers="colTitle1" class="ct-nowrap" style="padding-left:1em;">Plan Description:</td>
        <td headers="colData1" style="padding-left:1em"><p style="margin-top:0ex; margin-bottom:1ex;">Qualified researchers may request access to individual patient level data through the request platform (www.vivli.org). Further details on Roche's criteria for eligible studies are available here (https://vivli.org/ourmember/roche/).</p>
  <p style="margin-top:0ex; margin-bottom:1ex;">For further details on Roche's Global Policy on Sharing of Clinical Study Information and how to request access to related clinical study documents, see here (https://www.roche.com/research_and_development/who_we_are_how_we_work/clinical_trials/our_commitment_to_data_sharing.htm).</p></td>
      </tr>
                                      </tbody>
  </table>

    <br/>
  <table class="ct-layout_table tr-tableStyle tr-moreInfo" style="margin-top:1ex">
    <caption>Layout table for additional information</caption>
    <thead>
    <tr>
      <th id="colTitle2"></th>
      <th id="colData2"></th>
    </tr>
    </thead>
    <tbody>       
        <tr>
      <td headers="colTitle2" class="ct-nowrap">Studies a U.S. FDA-regulated Drug Product:</td>
      <td headers="colData2" style="padding-left:1em">Yes</td>
    </tr>
            <tr>
      <td headers="colTitle2" class="ct-nowrap">Studies a U.S. FDA-regulated Device Product:</td>
      <td headers="colData2" style="padding-left:1em">No</td>
    </tr>
                    </tbody>
  </table>
  
  
    <!-- keywords -->
    
    <!-- mesh terms -->
          <div class="tr-tableLabel">Additional relevant MeSH terms:</div>
      <div class="tr-indent3">
        <table class="ct-layout_table tr-meshTerms" style="width:100%;">
          <caption>Layout table for MeSH terms</caption>
          <thead>
          <tr>
            <th id="meshTermCol1" style="width:50%;"></th>
            <th id="meshTermCol2"></th>
          </tr>
          </thead>
          <tr>
            <td headers="meshTermCol1" style="padding-left:1em;">
                            Hemophilia A<br/>
                            Blood Coagulation Disorders, Inherited<br/>
                            Blood Coagulation Disorders<br/>
                            Hematologic Diseases<br/>
                          </td>
                        <td headers="meshTermCol1" style="padding-left:1em;">
                            Coagulation Protein Disorders<br/>
                            Hemorrhagic Disorders<br/>
                            Genetic Diseases, Inborn<br/>
                          </td>
                      </tr>
        </table>
      </div>
    
  <br/>

  <!--
        <span class="ct-body3">ClinicalTrials.gov processed this record on July 02, 2021</span><br/>
      -->
    <br/>  
  </div>
   </div>
						
			<div id="to-top"><a href="#wrapper">To Top</a></div>
			
			<div style="clear:both;"></div>
		</div>
	</div>
</div>  
<div>       <div id="for-footer">
        <ul class="ct-horz-list">
            <li style="border-left:0;"><a    href="/ct2/help/for-patient">For Patients and Families</a></li>
            <li><a href="/ct2/help/for-researcher">For Researchers</a></li>
            <li><a     href="/ct2/help/for-manager">For Study Record Managers</a></li>
        </ul>
    </div>

</div>  
<div id="footer-menu">
    <ul class="ct-horz-list">
		<li><a     href="/ct2/home">Home</a></li>
		<li><a     href="/ct2/resources/rss">RSS Feeds</a></li>
		<li><a     href="/ct2/sitemap">Site Map</a></li>
		<li><a     href="/ct2/about-site/terms-conditions">Terms and Conditions</a></li>
		<li><a     href="/ct2/about-site/disclaimer">Disclaimer</a></li>
		<li><a     href="https://support.nlm.nih.gov/knowledgebase/category/?id=CAT-01242&amp;category=clinicaltrials.gov&amp;hd_url=https%3A%2F%2Fclinicaltrials.gov%2Fct2%2Fshow%2FNCT02795767" onclick="openNewWindow('https://support.nlm.nih.gov/knowledgebase/category/?id=CAT-01242&amp;category=clinicaltrials.gov&amp;hd_url=https%3A%2F%2Fclinicaltrials.gov%2Fct2%2Fshow%2FNCT02795767'); return false">Customer Support</a></li>
	</ul>
</div>

</div>  
<div id="fine-print">
	<ul class="ct-horz-list">
		<li ><a title="NLM copyright information - opens new window"  href="https://www.nlm.nih.gov/copyright.html" onclick="openNewWindow('https://www.nlm.nih.gov/copyright.html'); return false"
>Copyright</a></li>
		<li ><a title="NLM privacy policy - opens new window"  href="https://www.nlm.nih.gov/privacy.html" onclick="openNewWindow('https://www.nlm.nih.gov/privacy.html'); return false"
>Privacy</a></li>
		<li ><a href="/ct2/accessibility" title="NLM Accessibility">Accessibility</a></li>
		<li ><a title="NLM viewers and players - opens new window"  href="https://www.nlm.nih.gov/plugins.html" onclick="openNewWindow('https://www.nlm.nih.gov/plugins.html'); return false"
>Viewers and Players</a></li>
		<li ><a title="NIH Freedom of Information Act office - opens new window"  href="https://www.nih.gov/icd/od/foia/index.htm" onclick="openNewWindow('https://www.nih.gov/icd/od/foia/index.htm'); return false"
>Freedom of Information Act</a></li>
		<li ><a title="USA.gov - opens new window"  href="https://www.usa.gov/" onclick="openNewWindow('https://www.usa.gov/'); return false"
>USA.gov</a></li>
	</ul>
    <ul class="ct-horz-list">
       <li><a title="U.S. National Library of Medicine - opens new window"  href="https://www.nlm.nih.gov/" onclick="openNewWindow('https://www.nlm.nih.gov/'); return false"
>U.S. National Library of Medicine</a></li>
       <li><a title="U.S. National Institutes of Health - opens new window"  href="https://www.nih.gov/" onclick="openNewWindow('https://www.nih.gov/'); return false"
>U.S. National Institutes of Health</a></li>
       <li><a title="U.S. Department of Health and Human Services - opens new window"  href="https://www.hhs.gov/" onclick="openNewWindow('https://www.hhs.gov/'); return false"
>
            U.S. Department of Health and Human Services</a></li>
    </ul>
</div>

<script type="text/javascript">__ncbi_sg_gaMode="clinicaltrials"</script>
<script type="text/javascript" src="/ct2/html/js/instrumentNCBIBaseJS.min.js?v=2"></script><noscript></noscript>
<script type="text/javascript" src="/ct2/html/js/main-glossary.js?v=44"></script><noscript></noscript>
<script type="text/javascript">
//OnSubmit routine - copy over some useful data and submit
function sendSearchPing() {
// Get pinger values
var cVals = ncbi.sg.getInstance()._cachedVals;
var app = cVals['ncbi_app'];
var db = cVals['ncbi_db'];
var pdid = cVals['ncbi_pdid'];
var pcid = cVals['ncbi_pcid'];
// Populate search details
var searchDetails = {};
searchDetails['jsevent'] = 'search';
searchDetails['searchtext'] = jQuery('#header-search-query').val();
if (app!=null) searchDetails['ncbi_app'] = app.value;
if (db!=null) searchDetails['ncbi_db'] = db.value;
if (pdid!=null) searchDetails['ncbi_pdid'] = pdid.value;
if (pcid!=null) searchDetails['ncbi_pcid'] = pcid.value;
// Send ping msg
ncbi.sg.ping(searchDetails);
};
</script>


</body>
</html>
